{"content":"<li class=\"n-box-item date-title\" data-end=\"1552535999\" data-start=\"1552449600\" data-txt=\"Monday, December 23, 2019\">Wednesday, March 13, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3442578\" data-ts=\"1552517465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDS\" target=\"_blank\">GDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442578-gds-holdings-plans-400m-in-ads-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GDS Holdings plans $400M in ADS offering</a></h4><ul>   <li>GDS Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings Limited'>GDS</a>) plans to offer American Depositary Shares in the <a href=\"https://seekingalpha.com/pr/17443511-gds-announces-launch-proposed-public-offering-adss\" target=\"_blank\">aggregate sum of $400M</a>.</li>    <li>Those are expected to trade on March 15. Each ADS represents eight class A ordinary shares.</li>    <li>Underwriters have a 30-day greenshoe option to buy up to $60M more at the offering price.</li>    <li>Net proceeds will be used for development and acquisition of new data centers, as well as general purposes.</li>    <li>Shares are <font color=\"red\">off 4.7%</font> postmarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442564-gds-holdings-minus-4_5-percent-amid-wider-loss-q4\" target=\"_blank\">GDS Holdings -4.5% amid wider loss in Q4</a> (Mar. 13 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442578\" data-linked=\"GDS Holdings plans $400M in ADS offering\" data-tweet=\"$GDS - GDS Holdings plans $400M in ADS offering https://seekingalpha.com/news/3442578-gds-holdings-plans-400m-in-ads-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3442578-gds-holdings-plans-400m-in-ads-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442575\" data-ts=\"1552516285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442575-htg-molecularminus-3_9-on-cowen-share-sale-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG Molecular -3.9% on Cowen share-sale deal</a></h4><ul>   <li>HTG Molecular Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics, Inc.'>HTGM</a>) has <font color=\"red\">slipped 3.9%</font> postmarket after an <a href=\"https://seekingalpha.com/filing/4402336\" target=\"_blank\">SEC filing</a> notes it's entered into a share sales agreement with Cowen and Co.</li>    <li>That covers time-to-time sales of shares with an aggregate offering price of $40M, to or through Cowen.</li>    <li>The shares have <font color=\"red\">fallen 31.9%</font> over the past three months, and are <font color=\"red\">down 47.4%</font> in the past six.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442575\" data-linked=\"HTG Molecular -3.9% on Cowen share-sale deal\" data-tweet=\"$HTGM - HTG Molecular -3.9% on Cowen share-sale deal https://seekingalpha.com/news/3442575-htg-molecularminus-3_9-on-cowen-share-sale-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3442575-htg-molecularminus-3_9-on-cowen-share-sale-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442573\" data-ts=\"1552515884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBW\" target=\"_blank\">BBW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442573-build-bearminus-8_7-on-reported-1_5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Build-A-Bear -8.7% on reported 1.5M-share offering</a></h4><ul>   <li>Build-A-Bear Workshop (NYSE:<a href='https://seekingalpha.com/symbol/BBW' title='Build-A-Bear Workshop, Inc.'>BBW</a>) has <font color=\"red\">fallen 8.7%</font> afer hours after Bloomberg notes plans to offer 1.5M shares via Morgan Stanley.</li>    <li>Those shares are expected to come at $5.25-$5.40, a discount of 8.3-10.9% from today's closing price of $5.89.</li>    <li>The seller is unknown, but one holder has that many shares, Bloomberg notes: Point72, with 2.98M.</li>    <li>Shares <font color=\"green\">increased just 0.2%</font> during the regular session after <a href=\"https://seekingalpha.com/news/3442197-build-bear-turns-page-challenging-fy18\" target=\"_blank\">mixed earnings results</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442573\" data-linked=\"Build-A-Bear -8.7% on reported 1.5M-share offering\" data-tweet=\"$BBW - Build-A-Bear -8.7% on reported 1.5M-share offering https://seekingalpha.com/news/3442573-build-bearminus-8_7-on-reported-1_5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3442573-build-bearminus-8_7-on-reported-1_5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442572\" data-ts=\"1552515388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGAN\" target=\"_blank\">EGAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442572-egainminus-8_9-on-proposed-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EGain -8.9% on proposed stock offering</a></h4><ul>   <li>Shares in eGain (NASDAQ:<a href='https://seekingalpha.com/symbol/EGAN' title='eGain Corporation'>EGAN</a>) are <font color=\"red\">off 8.9%</font> after hours following news of a <a href=\"https://seekingalpha.com/pr/17443414-egain-announces-proposed-public-offering-common-stock\" target=\"_blank\">proposed public stock offering</a>.</li>    <li>The company is selling all shares in the offering, though terms and size aren't yet disclosed.</li>    <li>Roth Capital Partners is the sole book-runner.</li>    <li>The company expects to grand underwriters a 30-day option to buy up to an additional 15% of shares on the same terms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442572\" data-linked=\"EGain -8.9% on proposed stock offering\" data-tweet=\"$EGAN - EGain -8.9% on proposed stock offering https://seekingalpha.com/news/3442572-egainminus-8_9-on-proposed-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3442572-egainminus-8_9-on-proposed-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442567\" data-ts=\"1552514518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDSY\" target=\"_blank\">IDSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442567-i-d-systems-to-acquire-pointer-telocation-for-140m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">I.D. Systems to acquire Pointer Telocation for $140M</a></h4><ul>   <li>I.D. Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/IDSY' title='I.D. Systems, Inc.'>IDSY</a>) is <font color=\"green\">up 20.1%</font> in thin after-hours trades after news that it's acquiring telematics/mobile IoT firm <a href=\"https://seekingalpha.com/pr/17443484-d-systems-acquire-pointer-telocation-leading-telematics-mobile-iot-solutions-company-140\" target=\"_blank\">Pointer Telocation for $140M</a>.</li>    <li>The deal's in cash and stock -- about $72M in cash and about 11M shares of newly created holding company PowerFleet.</li>    <li>The combined business generated $131M in revenue in 2018 (including $72M in recurring revenue) along with $14M in adjusted EBITDA.</li>    <li>\"We believe this is a transformative acquisition for I.D. Systems and our industry, as it combines our market and product leadership in North America with Pointer's technology leadership, supply chain acumen and broad international footprint,\" says CEO Chris Wolfe.</li>    <li>Some $3.5M in cost savings are expected within the first 12-18 months after closing, and the deal is expected to be accretive to non-GAAP EPS in the first 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442567\" data-linked=\"I.D. Systems to acquire Pointer Telocation for $140M\" data-tweet=\"$IDSY $PWFL - I.D. Systems to acquire Pointer Telocation for $140M https://seekingalpha.com/news/3442567-i-d-systems-to-acquire-pointer-telocation-for-140m?source=tweet\" data-url=\"https://seekingalpha.com/news/3442567-i-d-systems-to-acquire-pointer-telocation-for-140m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442560\" data-ts=\"1552513093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442560-after-hours-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After hours movers and shakers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/MLNT' title='Melinta Therapeutics, Inc.'>MLNT</a> <font color=\"green\">+18.0%</font>. <a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a> <font color=\"green\">+18.0%</font>. <a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a> <font color=\"green\">+12.8%</font>. <a href='https://seekingalpha.com/symbol/FLNT' title='Fluent, Inc.'>FLNT</a> <font color=\"green\">+11.1%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color=\"green\">+5.3%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color=\"red\">-16.1%</font>. <a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color=\"red\">-13.5%</font>. <a href='https://seekingalpha.com/symbol/BBW' title='Build-A-Bear Workshop, Inc.'>BBW</a> <font color=\"red\">-10.2%</font><a href='https://seekingalpha.com/symbol/SFS' title='Smart & Final Stores, Inc.'>SFS</a> <font color=\"red\">-8.7%</font>. <a href='https://seekingalpha.com/symbol/GMRE' title='Global Medical REIT Inc.'>GMRE</a> <font color=\"red\">-8.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442560\" data-linked=\"After hours movers and shakers\" data-tweet=\"$MLNT $MDB $DOMO - After hours movers and shakers https://seekingalpha.com/news/3442560-after-hours-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442560-after-hours-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442559\" data-ts=\"1552513019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIPR\" target=\"_blank\">IIPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442559-innovative-industrial-properties-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovative Industrial Properties beats on revenue</a></h4><ul><li>Innovative Industrial Properties (NYSE:<a href='https://seekingalpha.com/symbol/IIPR' title='Innovative Industrial Properties, Inc.'>IIPR</a>): Q4 AFFO of $0.38; FFO of $0.34.</li><li>Revenue of $4.78M (+109.6% Y/Y) <font color=\"green\">beats by $0.18M</font>.</li><li>Shares <font color=\"green\">+1.68%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/17443542-innovative-industrial-properties-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3442559\" data-linked=\"Innovative Industrial Properties beats on revenue\" data-tweet=\"$IIPR - Innovative Industrial Properties beats on revenue https://seekingalpha.com/news/3442559-innovative-industrial-properties-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3442559-innovative-industrial-properties-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442542\" data-ts=\"1552511274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMTC\" target=\"_blank\">SMTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442542-semtechminus-10-on-downside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semtech -10% on downside outlook</a></h4><ul><li>Semtech (NASDAQ:<a href='https://seekingalpha.com/symbol/SMTC' title='Semtech Corporation'>SMTC</a>) reports Q4 beats with a 14% Y/Y revenue growth. Downside Q1 guidance has revenue from $125M to $135M (consensus: $156.16M) and EPS from $0.30 to $0.36 (consensus: $0.51).</li><li>Earnings call started at 5 PM ET with a webcast<a href=\"https://investors.semtech.com/investor-relations\" target=\"_blank\"> here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17443444-semtech-announces-fourth-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a>.</li><li>Semtech shares <font color=\"red\">fell 10%</font> after resuming trading after the report.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442497-semtech-beats-0_02-beats-revenue\" target=\"_blank\">Semtech beats by $0.02, beats on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442542\" data-linked=\"Semtech -10% on downside outlook\" data-tweet=\"$SMTC - Semtech -10% on downside outlook https://seekingalpha.com/news/3442542-semtechminus-10-on-downside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3442542-semtechminus-10-on-downside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442532\" data-ts=\"1552510236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOMO\" target=\"_blank\">DOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442532-domoplus-8-on-q4-beats-upside-fy20-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Domo +8% on Q4 beats, upside FY20 outlook</a></h4><ul><li>Domo (NASDAQ:<a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a>) <font color=\"green\">gains 8%</font> on Q4 beats with 31% Y/Y revenue growth. Upside Q1 guidance has revenue from $40M to $41M (consensus: $39.16M) and EPS from -$1.30 to -$1.26 (consensus: -$1.41).</li><li>The upside FY20 outlook has revenue of $173M to $174M (consensus: $170M) and EPS of -$4.07 to -$3.99 (consensus: -$4.30).</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://www.globenewswire.com/Tracker?data=Yc-Vlc-UHwyU0o4BzYBM9DcvHAQ2cgbWeqDb8aINheH6JXZKdanhdcTbDi-FCuIOcbWa6iwAdHzW00TuDWiG6ZRGhyUoFWjBnka0molejlxK3e6XHTDx8zSr-SjpGPFf\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17443389-domo-announces-fourth-quarter-fiscal-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442472-domo-beats-0_30-beats-revenue\" target=\"_blank\">Domo beats by $0.30, beats on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442532\" data-linked=\"Domo +8% on Q4 beats, upside FY20 outlook\" data-tweet=\"$DOMO - Domo +8% on Q4 beats, upside FY20 outlook https://seekingalpha.com/news/3442532-domoplus-8-on-q4-beats-upside-fy20-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3442532-domoplus-8-on-q4-beats-upside-fy20-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442518\" data-ts=\"1552509390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDR\" target=\"_blank\">CLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442518-clouderaminus-14-on-q4-misses-downside-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloudera -14% on Q4 misses, downside guide</a></h4><ul><li>Cloudera (NYSE:<a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a>) <font color=\"red\">falls 14%</font> after Q4 results miss revenue and EPS estimates and include downside guidance. Note that the merger with Hortonworks closed on January 3.</li><li>The Q1 outlook has revenue from $187M to $190M (consensus: $219.01M) and EPS from -$0.25 to -$0.22 (consensus: -$0.04).</li><li>FY20 guidance has revenue from $835M to $855M (consensus: $942.19M) and EPS from -$0.36 to -$0.32 (consensus: $0.10).</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://investors.cloudera.com/home/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17443411-cloudera-reports-fourth-quarter-fiscal-year-2019-financial-results\" target=\"_blank\">Press release.</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3442482-cloudera-misses-0_08-misses-revenue\" target=\"_blank\">Cloudera misses by $0.08, misses on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442518\" data-linked=\"Cloudera -14% on Q4 misses, downside guide\" data-tweet=\"$CLDR - Cloudera -14% on Q4 misses, downside guide https://seekingalpha.com/news/3442518-clouderaminus-14-on-q4-misses-downside-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3442518-clouderaminus-14-on-q4-misses-downside-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442508\" data-ts=\"1552509025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXGT\" target=\"_blank\">AXGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442508-axovant-launches-stock-offering-shares-down-11-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant launches stock offering; shares down 11% after hours</a></h4><ul><li>Axovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGT' title='Axovant Sciences Ltd.'>AXGT</a>) is down <font color=\"red\">11%</font> after hours in response to its planned <a href=\"https://seekingalpha.com/pr/17443448-axovant-sciences-announces-public-offering-common-shares\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442508\" data-linked=\"Axovant launches stock offering; shares down 11% after hours\" data-tweet=\"$AXGT - Axovant launches stock offering; shares down 11% after hours https://seekingalpha.com/news/3442508-axovant-launches-stock-offering-shares-down-11-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3442508-axovant-launches-stock-offering-shares-down-11-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442507\" data-ts=\"1552508974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442507-tailored-brandsminus-9-after-weak-profit-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands -9% after weak profit outlook</a></h4><ul><li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a>) is <font color=\"red\">down 8.66%</font> in AH trading after the company warns of a down trend at Men's Wearhouse and Jos. A. Bank during Q4 and into Q1 of 2019.</li><li>CEO update: \"We attribute the current softness to both the macro-environment as well as the need for us to execute more quickly and effectively on our core growth strategies: deliver personalized products and services, create inspiring and seamless experiences in and across every channel, and build brands that stand for something more than just price. Our teams are intently focused on delivering against these objectives in fiscal 2019 as we look to build long-term sustainable value creation for our stakeholders.\"</li><li>The retailer expects a negative comp for Men's Wearhouse, Jos. A. Bank and Moores in Q1 and EPS of $0.10 to $0.15 vs. $0.51 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442495-tailored-brands-beats-0_01-misses-revenue\" target=\"_blank\">Tailored Brands beats by $0.01, misses on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442507\" data-linked=\"Tailored Brands -9% after weak profit outlook\" data-tweet=\"$TLRD - Tailored Brands -9% after weak profit outlook https://seekingalpha.com/news/3442507-tailored-brandsminus-9-after-weak-profit-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3442507-tailored-brandsminus-9-after-weak-profit-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442505\" data-ts=\"1552508869\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLNT\" target=\"_blank\">FLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442505-fluentplus-2_5-revenue-income-grow-25-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fluent +2.5% as revenue, income grow 25% in Q4</a></h4><ul>   <li>Fluent (NASDAQ:<a href='https://seekingalpha.com/symbol/FLNT' title='Fluent, Inc.'>FLNT</a>) is <font color=\"green\">up 2.5%</font> in early after-hours trading following a beat on top and bottom lines in its Q4 earnings report.</li>    <li>Revenues rose 25% and adjusted net income rose 25% as well, to $5.99M. EBITDA increased 4%, to $11.1M.</li>    <li>Media margin (measuring operating model efficiency) rose to $25.1M from $19.7M -- to 35.4% of revenue vs. a year-ago 34.9%.</li>    <li>Cash and equivalents came to $17.8M at year-end.</li>    <li>For Q1, it's guiding to revenue of $65.5M-$66.5M (17-19% Y/Y growth), with media margin of $22.5M-$23.5M, and EBITDA of $8.8M-$9.6M.</li>    <li>For the full year, it's forecasting revenue of $285M-$293M (14-17% Y/Y growth), with media margin of $100M-$106M and EBITDA of $46M-$50M (5-14% growth).</li>    <li><a href=\"http://investors.fluentco.com/\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442470-fluent-beats-0_02-beats-revenue\" target=\"_blank\">Fluent beats by $0.02, beats on revenue</a> (Mar. 13 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17443388-fluent-inc-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3442505\" data-linked=\"Fluent +2.5% as revenue, income grow 25% in Q4\" data-tweet=\"$FLNT - Fluent +2.5% as revenue, income grow 25% in Q4 https://seekingalpha.com/news/3442505-fluentplus-2_5-revenue-income-grow-25-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3442505-fluentplus-2_5-revenue-income-grow-25-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442503\" data-ts=\"1552508711\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APYX\" target=\"_blank\">APYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442503-apyx-medical-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apyx Medical EPS in-line, misses on revenue</a></h4><ul><li>Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>): Q4 GAAP EPS of -$0.10 in-line.</li><li>Revenue of $5.93M (+62.0% Y/Y) <font color=\"red\">misses by $0.02M</font>.</li><li>Shares <font color=\"green\">+1.35%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17443376-apyx-medical-corporation-reports-fourth-quarter-fiscal-year-2018-financial-results-introduces\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3442503\" data-linked=\"Apyx Medical EPS in-line, misses on revenue\" data-tweet=\"$APYX - Apyx Medical EPS in-line, misses on revenue https://seekingalpha.com/news/3442503-apyx-medical-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3442503-apyx-medical-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442496\" data-ts=\"1552508519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDB\" target=\"_blank\">MDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442496-mongodbplus-13-on-upside-fy20-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MongoDB +13% on upside FY20 outlook</a></h4><ul><li>MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) <font color=\"green\">gains 13%</font> after Q4 results that beat EPS and revenue estimates with 71% Y/Y revenue growth and upside guidance. Q1 has revenue from $82M to $84M (consensus: $74.96M) and EPS -$0.25 to -$0.23 (consensus: -$0.37).</li><li>Upside FY20 guidance has revenue from $363M to $371M (consensus: $347.39M) and EPS of -$1.06 to -$0.98 (consensus: -$1.28).</li><li>Revenue breakdown (ASC 606): Subscription, $80.6M (+73% Y/Y); Services, $4.9M (consensus: +37% Y/Y).</li><li>Earnings call starts at 5 PM ET with a webcast available <a href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=2402222-1&amp;h=1404505169&amp;u=https%3A%2F%2Finvestors.mongodb.com%2F&amp;a=https%3A%2F%2Finvestors.mongodb.com\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17443397-mongodb-inc-announces-fourth-quarter-full-year-fiscal-2019-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442471-mongodb-beats-0_21-beats-revenue\" target=\"_blank\">MongoDB beats by $0.21, beats on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442496\" data-linked=\"MongoDB +13% on upside FY20 outlook\" data-tweet=\"$MDB - MongoDB +13% on upside FY20 outlook https://seekingalpha.com/news/3442496-mongodbplus-13-on-upside-fy20-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3442496-mongodbplus-13-on-upside-fy20-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442491\" data-ts=\"1552508282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMRE\" target=\"_blank\">GMRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442491-global-medical-reitsminus-4_2-after-starting-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Medical REITS -4.2% after starting stock offering</a></h4><ul><li>Global Medical REIT (NYSE:<a href='https://seekingalpha.com/symbol/GMRE' title='Global Medical REIT Inc.'>GMRE</a>) <font color=\"red\">drops 4.2%</font> in after-hours trading after the company<a href=\"https://seekingalpha.com/pr/17443380-global-medical-reit-inc-commences-common-stock-public-offering\" target=\"_blank\"> starts a public offering</a> of common stock.</li><li>Sees greenshoe option for an additional 15% of shares being offered in the offering.</li><li>Plans to use proceeds to repay a part of outstanding credit debt and to fund acquisitions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442491\" data-linked=\"Global Medical REITS -4.2% after starting stock offering\" data-tweet=\"$GMRE - Global Medical REITS -4.2% after starting stock offering https://seekingalpha.com/news/3442491-global-medical-reitsminus-4_2-after-starting-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3442491-global-medical-reitsminus-4_2-after-starting-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442473\" data-ts=\"1552507815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VKTX\" target=\"_blank\">VKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442473-viking-therapeutics-beats-0_03\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viking Therapeutics beats by $0.03</a></h4><ul><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>): Q4 GAAP EPS of -$0.07 beats by $0.03.</li><li>Cash and equivalents of $24.78M (+175.9% Y/Y)</li><li>Shares <font color=\"green\">+4.97%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17443398-viking-therapeutics-reports-fourth-quarter-year-end-2018-financial-results-provides-corporate\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3442473\" data-linked=\"Viking Therapeutics beats by $0.03\" data-tweet=\"$VKTX - Viking Therapeutics beats by $0.03 https://seekingalpha.com/news/3442473-viking-therapeutics-beats-0_03?source=tweet\" data-url=\"https://seekingalpha.com/news/3442473-viking-therapeutics-beats-0_03\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442469\" data-ts=\"1552507671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVRA\" target=\"_blank\">SVRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442469-savara-beats-0_07\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Savara beats by $0.07</a></h4><ul><li>Savara (NASDAQ:<a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a>): Q4 GAAP EPS of -$0.29 <font color=\"green\">beats by $0.07</font>.</li><li>Cash, equivalents and short-term investments of $110.83M (+17.5% Y/Y)</li><li>Shares <font color=\"green\">+1.98%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17443373-savara-reports-fourth-quarter-full-year-2018-financial-results-provides-business-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3442469\" data-linked=\"Savara beats by $0.07\" data-tweet=\"$SVRA - Savara beats by $0.07 https://seekingalpha.com/news/3442469-savara-beats-0_07?source=tweet\" data-url=\"https://seekingalpha.com/news/3442469-savara-beats-0_07\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442465\" data-ts=\"1552507484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACTG\" target=\"_blank\">ACTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442465-acacia-research-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia Research reports Q4 results</a></h4><ul><li>Acacia Research (NASDAQ:<a href='https://seekingalpha.com/symbol/ACTG' title='Acacia Research Corporation'>ACTG</a>): Q4 Non-GAAP EPS of $0.41; GAAP EPS of -$0.23.</li><li>Revenue of $49.2M (+1322.0% Y/Y)</li><li>Shares <font color=\"green\">+6.2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17443351-acacia-research-reports-fourth-quarter-full-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3442465\" data-linked=\"Acacia Research reports Q4 results\" data-tweet=\"$ACTG - Acacia Research reports Q4 results https://seekingalpha.com/news/3442465-acacia-research-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3442465-acacia-research-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442460\" data-ts=\"1552506543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEIX\" target=\"_blank\">PEIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442460-pacific-ethanol-downgraded-roth-citing-cash-burn-weak-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Ethanol downgraded at Roth citing cash burn, weak margins</a></h4><ul><li>Pacific Ethanol (<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='red'>-9%</font>) continues to spiral downward following its Q4 miss, and Roth Capital follows up by <a href=\"https://thefly.com/thestreet/realmoney/index.php/PEIXid2878703/PEIX-Pacific-Ethanol-downgraded-to-Neutral-from-Buy-at-Roth-Capital\" target=\"_blank\">downgrading</a> the stock to Neutral from Buy with a $1.50 price target, slashed from $7.00.</li><li>With the Q4 cash burn and \"weak\" current margin environment, the company's operational flexibility is \"incrementally constrained,\" Roth analyst Craig Irwin writes, believing PEIX may have problems funding its cost reduction efforts and that its additional $69M parent notes coming due in December \"create additional uncertainty.\"</li><li>Irwin sees asset sales as essential to facilitate delevering and cites \"elevated risks\" for his downgrade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442460\" data-linked=\"Pacific Ethanol downgraded at Roth citing cash burn, weak margins\" data-tweet=\"$PEIX - Pacific Ethanol downgraded at Roth citing cash burn, weak margins https://seekingalpha.com/news/3442460-pacific-ethanol-downgraded-roth-citing-cash-burn-weak-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3442460-pacific-ethanol-downgraded-roth-citing-cash-burn-weak-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442458\" data-ts=\"1552505876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLGT\" target=\"_blank\">TLGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442458-teligent-up-15-ahead-of-q4-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teligent up 15% ahead of Q4 report</a></h4><ul><li>Thinly traded nano cap Teligent (<a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a> <font color=\"green\">+15.1%</font>) is up on more than a 5x surge in volume on no particular news.</li><li>The company will report Q4 results on Monday, March 18. Consensus view is a loss/share of ($0.03) on revenues of $18.1M.</li><li>In January, the FDA approved its generic version of Clobetasol Propionate Ointment.</li><li>At the end of September 2018, it had $15.3M in cash and equivalents while operations consumed $15.3M during the first three quarters of the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442458\" data-linked=\"Teligent up 15% ahead of Q4 report\" data-tweet=\"$TLGT - Teligent up 15% ahead of Q4 report https://seekingalpha.com/news/3442458-teligent-up-15-ahead-of-q4-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3442458-teligent-up-15-ahead-of-q4-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442455\" data-ts=\"1552504896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YETI\" target=\"_blank\">YETI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442455-yetiplus-7-after-dicks-reports-shows-brand-momentum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yeti +7% after Dick&#39;s reports shows brand momentum</a></h4><ul><li>Yeti Holdings (<a href='https://seekingalpha.com/symbol/YETI' title='YETI Holdings, Inc.'>YETI</a> <font color='green'>+7.5%</font>) rallies to new heights after Jefferies points to the strong demand for the company's products tipped off in the Dick's earnings report.</li><li>\"DKS continues to allocate greater resources to the brand, and we wouldn\u2019t be surprised to see further floor space growth ahead,\" notes Jefferies analyst Randal Konik.</li><li>Shares of Yeti traded at a new high of $27.10 earlier in the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442455\" data-linked=\"Yeti +7% after Dick&#39;s reports shows brand momentum\" data-tweet=\"$YETI - Yeti +7% after Dick&#39;s reports shows brand momentum https://seekingalpha.com/news/3442455-yetiplus-7-after-dicks-reports-shows-brand-momentum?source=tweet\" data-url=\"https://seekingalpha.com/news/3442455-yetiplus-7-after-dicks-reports-shows-brand-momentum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442454\" data-ts=\"1552504727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTX\" target=\"_blank\">UTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442454-defense-stocks-end-slide-after-release-of-750b-federal-budget\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Defense stocks end slide after release of $750B federal budget</a></h4><ul><li>Aerospace and defense stocks are on the rise after the U.S. FY 2020 defense budget was released earlier this week: United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color=\"green\">+1.3%</font>), Huntington Ingalls (<a href='https://seekingalpha.com/symbol/HII' title='Huntington Ingalls Industries, Inc.'>HII</a> <font color=\"green\">+2.1%</font>), Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color=\"green\">+0.7%</font>), General Dynamics (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color=\"green\">+1.7%</font>), Northrop Grumman (<a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color=\"green\">+1.1%</font>).</li><li>The Trump administration's proposed $750B budget drew mixed responses; Bernstein analysts note the budget represented an increase of 4.8%, or 3.3% excluding border wall funding, in line with their expectations.</li><li>Baird's Peter Arment believes the <a href=\"https://www.barrons.com/articles/buy-defense-stocks-because-military-spending-is-on-the-rise-analysts-say-51552495159\" target=\"_blank\">budget number is a win</a> and says \"the defense recapitalization theme is well intact,\" meaning the government is moving to replace old equipment.</li><li>But Morgan Stanley analyst Rajeev Lalwani says the proposal is \"lackluster\" and not likely to make it through Congress in the current form.</li><li>The $750B headline budget is \"at the upper end of expectations but light on investment funding,\" Lalwani writes. \"The mix of funds indicates a prioritization of research and development while trimming procurement, netting about 2% growth, shy of mid-single-digit expectations.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3442454\" data-linked=\"Defense stocks end slide after release of $750B federal budget\" data-tweet=\"$UTX $HII $RTN - Defense stocks end slide after release of $750B federal budget https://seekingalpha.com/news/3442454-defense-stocks-end-slide-after-release-of-750b-federal-budget?source=tweet\" data-url=\"https://seekingalpha.com/news/3442454-defense-stocks-end-slide-after-release-of-750b-federal-budget\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442449\" data-ts=\"1552503654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442449-technology-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers</a></h4><ul><li><strong>Gainers:</strong> Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">+23%</font>. SemiLEDs (NASDAQ:<a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a>) <font color=\"green\">+16%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a>) <font color=\"green\">+10%</font>. BSQUARE (NASDAQ:<a href='https://seekingalpha.com/symbol/BSQR' title='BSQUARE Corporation'>BSQR</a>) <font color=\"green\">+9%</font>. ACM Research (NASDAQ:<a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a>) <font color=\"green\">+7%</font>.</li> <li><strong>Losers: </strong>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-27%</font>. Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <font color=\"red\">-19%</font>. MicroVision (NASDAQ:<a href='https://seekingalpha.com/symbol/MVIS' title='MicroVision, Inc.'>MVIS</a>) <font color=\"red\">-17%</font>. HC2 Holdings (NYSE:<a href='https://seekingalpha.com/symbol/HCHC' title='HC2 Holdings, Inc.'>HCHC</a>) <font color=\"red\">-13%</font>.NantHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth, Inc.'>NH</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442449\" data-linked=\"Technology - Top 5 Gainers / Losers\" data-tweet=\"$TEUM $LEDS $QTT - Technology - Top 5 Gainers / Losers https://seekingalpha.com/news/3442449-technology-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442449-technology-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442441\" data-ts=\"1552501331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442441-petrobras-reopens-bidding-for-tag-pipeline-network-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras reopens bidding for TAG pipeline network - Reuters</a></h4><ul><li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petróleo Brasileiro S.A. - Petrobras'>PBR</a> <font color='green'>+3%</font>) has relaunched the <a href=\"https://www.reuters.com/article/us-petrobras-divestiture-tag/petrobras-reopens-bidding-for-pipeline-network-tag-sources-idUSKCN1QU2GI\" target=\"_blank\">process to allow second round bids</a> for the TAG pipeline network, Reuters reports.</li><li>PBR has finished drafting a sale contract with Engie (<a href='https://seekingalpha.com/symbol/ENGIY' title='ENGIE SA'>OTCPK:ENGIY</a>), the winner of the first phase of the process which is bidding with Canadian pension fund Caisse de Dépot et Placement du Québec.</li><li>Yesterday, the other two groups received from documents needed to offer new bids for TAG, which reportedly may be delivered over the coming weeks; the groups will not have access to the exact price offered by Engie, but the French company's bid is said to total ~$8B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442441\" data-linked=\"Petrobras reopens bidding for TAG pipeline network - Reuters\" data-tweet=\"$PBR $PBR $ENGIY - Petrobras reopens bidding for TAG pipeline network - Reuters https://seekingalpha.com/news/3442441-petrobras-reopens-bidding-for-tag-pipeline-network-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3442441-petrobras-reopens-bidding-for-tag-pipeline-network-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442433\" data-ts=\"1552500243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442433-navistarminus-5-after-volkswagen-scraps-traton-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar -5% after Volkswagen scraps Traton IPO</a></h4><ul> <li>Navistar (NYSE:<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>) is <font color=\"red\">down 4.66%</font> after Volkswagen scraps plans for an IPO of its Traton truck unit.</li> <li>There has been some speculation swirling around over the last year that Volkswagen could launch a full takeover of Navistar with funds brought in from a potential Traton offering.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3442350-volkswagen-delays-traton-ipo\" target=\"_blank\">Volkswagen delays Traton IPO</a> (March 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442433\" data-linked=\"Navistar -5% after Volkswagen scraps Traton IPO\" data-tweet=\"$NAV - Navistar -5% after Volkswagen scraps Traton IPO https://seekingalpha.com/news/3442433-navistarminus-5-after-volkswagen-scraps-traton-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3442433-navistarminus-5-after-volkswagen-scraps-traton-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442432\" data-ts=\"1552500232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442432-flexible-solutions-international-and-bristow-group-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexible Solutions International and Bristow Group among Energy/Materials gainers; SAExploration and DRDGOLD among losers</a></h4><ul><li><b>Gainers: </b>Flexible Solutions International (NYSEMKT:<a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International, Inc'>FSI</a>) <font color=\"green\">+14%</font>. Bristow Group (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"green\">+14%</font>. Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc.'>LGCY</a>) <font color=\"green\">+9%</font>. SenesTech (NASDAQ:<a href='https://seekingalpha.com/symbol/SNES' title='SenesTech, Inc.'>SNES</a>) <font color=\"green\">+9%</font>. Abraxas Petroleum (NASDAQ:<a href='https://seekingalpha.com/symbol/AXAS' title='Abraxas Petroleum Corporation'>AXAS</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>SAExploration (NASDAQ:<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a>) <font color=\"red\">-10%</font>. DRDGOLD (NYSE:<a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a>) <font color=\"red\">-9%</font>. Pacific Ethanol (NASDAQ:<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a>) <font color=\"red\">-8%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"red\">-7%</font>. SSR Mining (NASDAQ:<a href='https://seekingalpha.com/symbol/SSRM' title='SSR Mining Inc.'>SSRM</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442432\" data-linked=\"Flexible Solutions International and Bristow Group among Energy/Materials gainers; SAExploration and DRDGOLD among losers\" data-tweet=\"$FSI $BRS $LGCY - Flexible Solutions International and Bristow Group among Energy/Materials gainers; SAExploration and DRDGOLD among losers https://seekingalpha.com/news/3442432-flexible-solutions-international-and-bristow-group-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442432-flexible-solutions-international-and-bristow-group-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442431\" data-ts=\"1552500181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNLI\" target=\"_blank\">DNLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442431-denali-files-for-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Denali files for mixed shelf offering</a></h4><ul><li>Denali Therapeutics (<a href='https://seekingalpha.com/symbol/DNLI' title='Denali Therapeutics Inc.'>DNLI</a> <font color=\"green\">+8.2%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1714899/000171489919000018/forms-3asr31219.htm\" target=\"_blank\">prospectus </a>for an unspecified mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442431\" data-linked=\"Denali files for mixed shelf offering\" data-tweet=\"$DNLI - Denali files for mixed shelf offering https://seekingalpha.com/news/3442431-denali-files-for-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3442431-denali-files-for-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442430\" data-ts=\"1552499951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442430-report-cbs-nbc-swap-super-bowls-around-olympic-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: CBS, NBC swap Super Bowls around Olympic coverage</a></h4><ul>   <li>CBS Sports (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color=\"red\">-1.8%</font>) and NBC Sports (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color=\"green\">+0.5%</font>) are <a href=\"https://nypost.com/2019/03/13/why-nbc-and-cbs-are-trading-super-bowls/\" target=\"_blank\">swapping Super Bowls</a> in a move to benefit each company.</li>    <li>CBS, originally set to broadcast the 2022 NFL championship, will now broadcast the game in 2021, while NBC will fall back to 2022, the <i>New York Post</i> reports. No compensation is changing hands.</li>    <li>The reason is Olympic: NBC would like to pair its 2022 game with the 2022 Winter Olympic Games, a move that should make selling advertising easier via combo deals.</li>    <li>And in moving to 2021, CBS gets a Super Bowl that doesn't compete with the Olympics. The 2022 Super Bowl is set for Feb. 6, two days after the Feb. 4 Olympic opening that year.</li>    <li>Network contracts for the Big Game are set for renegotiation after the 2023 Super Bowl.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442430\" data-linked=\"Report: CBS, NBC swap Super Bowls around Olympic coverage\" data-tweet=\"$VIAC $CMCSA - Report: CBS, NBC swap Super Bowls around Olympic coverage https://seekingalpha.com/news/3442430-report-cbs-nbc-swap-super-bowls-around-olympic-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3442430-report-cbs-nbc-swap-super-bowls-around-olympic-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442405\" data-ts=\"1552498342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNAT\" target=\"_blank\">CNAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442405-conatus-up-22-ahead-of-emricasan-data-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conatus up 22% ahead of Emricasan data presentation</a></h4><ul><li>Nano cap Conatus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a> <font color=\"green\">+22.2%</font>) is up on more than a 4x surge in volume. Shares have rallied <font color=\"green\">43%</font> this week.</li><li>Today, the company <a href=\"https://seekingalpha.com/pr/17442841-conatus-late-breaker-oral-presentation-easl-meeting-detail-results-encore-ph-phase-2b\" target=\"_blank\">announced </a>that detailed results from the Phase 2b <a href=\"https://clinicaltrials.gov/ct2/show/NCT02960204?lead=conatus&amp;rank=3\" target=\"_blank\">ENCORE-PH</a> study evaluating emricasan in patients with NASH cirrhosis and severe portal hypertension will be presented on April 13 at the European Association for the Study of the Liver Annual Meeting in Vienna.</li><li>Topline data from two other mid-stage studies, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02686762?lead=conatus&amp;rank=4\" target=\"_blank\">ENCORE-NF</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT03205345?lead=conatus&amp;rank=2\" target=\"_blank\">ENCORE-LF</a>, will be released in the coming months.</li><li>Selected NASH-related tickers: Madrigal Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a> <font color=\"green\">+3.8%</font>), Viking Therapeutics (<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a> <font color=\"green\">+4.3%</font>), Can-Fite BioPharma (<a href='https://seekingalpha.com/symbol/CANF' title='Can-Fite BioPharma Ltd.'>CANF</a> <font color=\"red\">-3%</font>), Lipocine (<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color=\"red\">-10.9%</font>), Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals, Inc.'>ICPT</a> <font color=\"green\">+2.9%</font>), CymaBay Therapeutics (<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a> <font color=\"green\">+0.5%</font>), Galectin Therapeutics (<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color=\"red\">-1.1%</font>), Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color=\"green\">+1.4%</font>), Enanta Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ENTA' title='Enanta Pharmaceuticals, Inc.'>ENTA</a> <font color=\"red\">-0.2%</font>), Genfit SA (<a href='https://seekingalpha.com/symbol/GNFTF' title='Genfit SA'>OTCPK:GNFTF</a>), Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"green\">+1.4%</font>), Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"green\">+0.8%</font>), Wave Life Sciences (<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a> <font color=\"red\">-1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442405\" data-linked=\"Conatus up 22% ahead of Emricasan data presentation\" data-tweet=\"$CNAT $MDGL $VKTX - Conatus up 22% ahead of Emricasan data presentation https://seekingalpha.com/news/3442405-conatus-up-22-ahead-of-emricasan-data-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3442405-conatus-up-22-ahead-of-emricasan-data-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442404\" data-ts=\"1552498247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442404-take-two-rallies-on-5-gains-amid-sony-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two rallies on with 5% gains amid Sony chatter</a></h4><ul>   <li>With traders jawing about a potential takeover by Sony (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color=\"green\">+1%</font>), Take-Two Interactive Software (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) has added to a three-day rally with <font color=\"green\">gains of 5.4%</font> today.</li>    <li>Take-Two has been the subject of merger/acquisition speculation at numerous times in the past few years.</li>    <li>A higher close today would be the company's fourth straight higher finish; shares are <font color=\"green\">8.8% higher</font> so far this week.</li>    <li>That's a comfortable rebound for longs who have endured a <font color=\"red\">31.2% drop</font> over the past six months, a tough season for some sector participants.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442404\" data-linked=\"Take-Two rallies on with 5% gains amid Sony chatter\" data-tweet=\"$TTWO $SNE - Take-Two rallies on with 5% gains amid Sony chatter https://seekingalpha.com/news/3442404-take-two-rallies-on-5-gains-amid-sony-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3442404-take-two-rallies-on-5-gains-amid-sony-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442403\" data-ts=\"1552497988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442403-investors-gauge-risk-airline-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors gauge risk with airline stocks</a></h4><ul> <li>Airline stocks are recovering from two days of selling pressure following the Boeing 737 Max 8 crash last weekend.</li> <li>Gainers today include American Airlines Group (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group Inc.'>AAL</a> <font color='green'>+2.2%</font>), United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc.'>UAL</a> <font color='green'>+1.6%</font>), Alaska Airlines Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='green'>+2.4%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+1.3%</font>) and Hawaiian Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color='green'>+3.3%</font>).</li> <li>Related ETF: <a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3442403\" data-linked=\"Investors gauge risk with airline stocks\" data-tweet=\"$AAL $UAL $ALK - Investors gauge risk with airline stocks https://seekingalpha.com/news/3442403-investors-gauge-risk-airline-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3442403-investors-gauge-risk-airline-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442401\" data-ts=\"1552497951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NRE\" target=\"_blank\">NRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442401-northstar-realty-europeminus-4_7-after-q4-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NorthStar Realty Europe -4.7% after Q4 revenue miss</a></h4><ul><li>NorthStar Realty Europe (NYSE:<a href='https://seekingalpha.com/symbol/NRE' title='Northstar Realty Europe Corp.'>NRE</a>) <font color=\"red\">slumps 4.7%</font> after <a href=\"http://ir.nrecorp.com/static-files/165e18bc-489f-4df9-8943-d4603bef6efe\" target=\"_blank\">Q4 total revenue</a> of $28.4M fell short of the consensus estimate of $29.2M and fell 13% from the year-ago quarter.</li><li>Q4 cash available for distribution of 22 cents per share fell from 23 cents in the year-ago quarter.</li><li>Q4 adjusted EBITDA of $15.5M fell from $15.9M in Q3 and $16.3M in Q4 2017.</li><li>Q4 same-store net operating income increased 16% on increased recoverability of operating expenses and the year-ago quarter included a $0.9M write-off of straight-line rent related to an early termination at Portman Square.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442277-northstar-realty-europe-misses-revenue\" target=\"_blank\">NorthStar Realty Europe misses on revenue</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442401\" data-linked=\"NorthStar Realty Europe -4.7% after Q4 revenue miss\" data-tweet=\"$NRE - NorthStar Realty Europe -4.7% after Q4 revenue miss https://seekingalpha.com/news/3442401-northstar-realty-europeminus-4_7-after-q4-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3442401-northstar-realty-europeminus-4_7-after-q4-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442398\" data-ts=\"1552497646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442398-pareteumplus-23_5-to-three-year-highs-spurred-revenue-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +23.5% to three-year highs, spurred by revenue growth</a></h4><ul>   <li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is rallying hard after earnings, <font color=\"green\">up 23.5%</font> and one of Nasdaq's top movers after <a href=\"https://seekingalpha.com/news/3442029-pareteum-plus-4_9-percent-revenue-jumps-multiples-guidance-stays-high\" target=\"_blank\">revenue more than tripled</a> year-over-year and the company produced a solid forecast for 2019.</li>    <li>Shares today have reached their highest point in nearly three years, since the company was Elephant Talk Communications.</li>    <li>The 36-month backlog of $615M provides \"significant visibility\" into revenue potential, Chairman Hal Turner says on the company's call, noting also that Pareteum expects EBITDA and cash flows to turn positive by midyear.</li>    <li><a href=\"https://seekingalpha.com/article/4248300-pareteum-corporation-teum-ceo-vic-bozzo-q4-2018-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3442398\" data-linked=\"Pareteum +23.5% to three-year highs, spurred by revenue growth\" data-tweet=\"$TEUM - Pareteum +23.5% to three-year highs, spurred by revenue growth https://seekingalpha.com/news/3442398-pareteumplus-23_5-to-three-year-highs-spurred-revenue-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3442398-pareteumplus-23_5-to-three-year-highs-spurred-revenue-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442396\" data-ts=\"1552497478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZTO\" target=\"_blank\">ZTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442396-zto-expressminus-4-on-margin-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZTO Express -4% on margin worries</a></h4><ul> <li>ZTO Express (NYSE:<a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express &#40;Cayman&#41; Inc.'>ZTO</a>) is <font color=\"red\">down 3.90%</font> after the company's margin drop in <a href=\"https://seekingalpha.com/pr/17442124-zto-reports-fourth-quarter-fiscal-year-2018-unaudited-financial-results\" target=\"_blank\">Q4</a> startled investors.</li> <li>ZTO's gross margin rate was reported at 27.5% of sales vs. 31.% a year ago and the consensus expectation of 29.2%. The company says the decrease in gross margin was mainly driven by parcel volume growth.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3442396\" data-linked=\"ZTO Express -4% on margin worries\" data-tweet=\"$ZTO - ZTO Express -4% on margin worries https://seekingalpha.com/news/3442396-zto-expressminus-4-on-margin-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3442396-zto-expressminus-4-on-margin-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442395\" data-ts=\"1552497373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTIV\" target=\"_blank\">OTIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442395-on-track-innovations-down-15-on-q4-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">On Track Innovations down 15% on Q4 earnings miss</a></h4><div><ul><li>On Track Innovations (<a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd.'>OTIV</a> <font color=\"red\">-15.2%</font>) reported Q4 revenue decrease of 28.4% Y/Y to $4.53M, reflecting lower level of orders from the Asia-Pacific region and tariffs implemented by the United States on imports from China.</li><li>Recurring revenues, on an absolute dollar basis, were $1.2M (26% of revenues).</li><li>Q4 Gross margin <font color=\"green\">improved by 147 bps</font> to 47.9%.</li><li>Adj. EBITDA loss from continuing operations of $356k, compared to adj. EBITDA loss of $673k in 2017.</li><li>Q4 Expenses: R&amp;D $782k (-10.9% Y/Y); Selling &amp; Marketing $1.24M (-15.5% Y/Y); and G&amp;A $978k (-11.3% Y/Y).</li><li>Net cash used in continuing operating activities YTD was $2.18M, compared to $3.13M a year ago.</li><li>Cash and cash equivalents at the end of the year was $5.11M, compared to $7.79M a year ago.</li><li>OTI has taken steps to relocate manufacturing to other locations, after the tariffs implemented by the United States on imports from China, where the Company manufactures its products.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442195-track-innovations-misses-0_01-misses-revenue\" target=\"_blank\">On Track Innovations misses by $0.01, misses on revenue</a> (March 13)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3442395\" data-linked=\"On Track Innovations down 15% on Q4 earnings miss\" data-tweet=\"$OTIV - On Track Innovations down 15% on Q4 earnings miss https://seekingalpha.com/news/3442395-on-track-innovations-down-15-on-q4-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3442395-on-track-innovations-down-15-on-q4-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442383\" data-ts=\"1552496499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GH\" target=\"_blank\">GH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442383-guardant-health-up-25-on-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guardant Health up 25% on Q4 beat</a></h4><ul><li>Guardant Health (<a href='https://seekingalpha.com/symbol/GH' title='Guardant Health, Inc.'>GH</a> <font color=\"green\">+25.3%</font>) is up on 4x normal volume following its Q4 report released after the close yesterday that <a href=\"https://seekingalpha.com/news/3442056-guardant-health-beats-0_05-beats-revenue\" target=\"_blank\">beat expectations</a>. Highlights:</li><li>Revenue was up 64% to $32.9M; oncology testing revenue was up 98% to $28.1M.</li><li>Net loss was ($25.1M).</li><li>Company working with AstraZeneca on developing Guardant360 and GuardantOMNI tests as companion diagnostics for Tagrisso and Imfinzi, respectively.</li><li><strong>2019 guidance</strong>: Revenue: $130M - 135M; net loss: ($129M - 126M).</li></ul><div class=\"tiny-share-widget\" data-id=\"3442383\" data-linked=\"Guardant Health up 25% on Q4 beat\" data-tweet=\"$GH - Guardant Health up 25% on Q4 beat https://seekingalpha.com/news/3442383-guardant-health-up-25-on-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3442383-guardant-health-up-25-on-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442382\" data-ts=\"1552496346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442382-oaktree-capital-group-leads-financial-gainers-owens-realty-mortgage-and-ready-capital-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oaktree Capital Group leads financial gainers; Owens Realty Mortgage and Ready Capital among losers</a></h4><ul><li><b>Gainers:</b> Oaktree Capital Group (NYSE:<a href='https://seekingalpha.com/symbol/OAK' title='Oaktree Capital Group, LLC'>OAK</a>) <font color=\"green\">+12%</font>. Mogo Finance Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MOGO' title='Mogo Finance Technology Inc.'>MOGO</a>) <font color=\"green\">+7%</font>. Genworth Financial (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-13%</font>. Owens Realty Mortgage (NYSEMKT:<a href='https://seekingalpha.com/symbol/ORM' title='Owens Realty Mortgage, Inc.'>ORM</a>) <font color=\"red\">-5%</font>. Ready Capital (NYSE:<a href='https://seekingalpha.com/symbol/RC' title='Ready Capital Corporation'>RC</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442382\" data-linked=\"Oaktree Capital Group leads financial gainers; Owens Realty Mortgage and Ready Capital among losers\" data-tweet=\"$OAK $MOGO $GNW - Oaktree Capital Group leads financial gainers; Owens Realty Mortgage and Ready Capital among losers https://seekingalpha.com/news/3442382-oaktree-capital-group-leads-financial-gainers-owens-realty-mortgage-and-ready-capital-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3442382-oaktree-capital-group-leads-financial-gainers-owens-realty-mortgage-and-ready-capital-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442378\" data-ts=\"1552495675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442378-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+177%</font>. Pareteum Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">+26%</font>. Clean Energy Fuels (NASDAQ:<a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a>) <font color=\"green\">+25%</font>. Guardant Health (NASDAQ:<a href='https://seekingalpha.com/symbol/GH' title='Guardant Health, Inc.'>GH</a>) <font color=\"green\">+24%</font>. Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>) <font color=\"green\">+21%</font>. Natera (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRA' title='Natera, Inc.'>NTRA</a>) <font color=\"green\">+20%</font>. Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a>) <font color=\"green\">+18%</font>. Avalon Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/AWX' title='Avalon Holdings Corporation'>AWX</a>) <font color=\"green\">+18%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"green\">+17%</font>. Ballantyne Strong (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc'>BTN</a>) <font color=\"green\">+16%</font>.</li> <li><strong>Losers: </strong>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) <font color=\"red\">-25%</font>. VivoPower International PLC (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-25%</font>. Ocean Power Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a>) <font color=\"red\">-22%</font>. INSYS Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/INSY' title='INSYS Therapeutics, Inc.'>INSY</a>) <font color=\"red\">-20%</font>. BlueLinx Holdings (NYSE:<a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings Inc.'>BXC</a>) <font color=\"red\">-20%</font>. Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>) <font color=\"red\">-19%</font>. Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <font color=\"red\">-18%</font>. Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) <font color=\"red\">-17%</font>. Clearwater Paper Corporation (NYSE:<a href='https://seekingalpha.com/symbol/CLW' title='Clearwater Paper Corporation'>CLW</a>) <font color=\"red\">-16%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442378\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$AKTX $TEUM $CLNE - Midday Gainers / Losers https://seekingalpha.com/news/3442378-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442378-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442372\" data-ts=\"1552494985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BXC\" target=\"_blank\">BXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442372-bluelinx-holdings-down-19-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlueLinx Holdings down 19% post Q4 results</a></h4><div><ul><li>BlueLinx Holdings (<a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings Inc.'>BXC</a> <font color=\"red\">-19.9%</font>) reported Q4 revenue growth of 55.2% Y/Y to $673M; and Pro forma net sales were down by 13.3% Y/Y.</li><li>Company recorded a net loss of $16.17M for the quarter, compared to net income of $53.48M a year ago.</li><li>Q4 Gross margin <font color=\"red\">declined by 74 bps</font> to 12.1%; and operating margin <font color=\"red\">fell by 197 bps</font> to -1.1%.</li><li>Adj. EBITDA was $6.78M (-31% Y/Y) and margin <font color=\"red\">declined by 126 bps</font> to 1.01%.</li><li>SG&amp;A expenses were $80.66M (+63.2% Y/Y) and margin of 11.9% <font color=\"red\">up by 60 bps</font>.</li><li>Net cash provided by operating activities YTD was $41.56M, compared to $2.5M used a year ago.</li><li>Company mentioned that Integration efforts realized through December 2018 should result in annual synergies exceeding $30M in 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442186-bluelinx-holdings-reports-q4-results\" target=\"_blank\">BlueLinx Holdings reports Q4 results</a> (March 13)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3442372\" data-linked=\"BlueLinx Holdings down 19% post Q4 results\" data-tweet=\"$BXC - BlueLinx Holdings down 19% post Q4 results https://seekingalpha.com/news/3442372-bluelinx-holdings-down-19-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3442372-bluelinx-holdings-down-19-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442374\" data-ts=\"1552494858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEIX\" target=\"_blank\">PEIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442374-pacific-ethanolminus-2-q4-loss-doubles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Ethanol -2% as Q4 loss more than doubles</a></h4><ul><li>Pacific Ethanol (<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='red'>-1.9%</font>) is lower after its <a href=\"https://seekingalpha.com/news/3442018-pacific-ethanol-misses-revenue\" target=\"_blank\">Q4 loss</a> more than doubled to $34.5M and revenues fell 15% Y/Y to $334M as demand weakened and ethanol prices fell.</li><li>For the full year, PEIX's loss mounted to $67.9M from $38.1M in 2017, and revenues dropped 7% to $1.52B.</li><li>PEIX says Q4 results were hurt by \"market  conditions, regulatory uncertainty and trade disputes, which compressed  production margins to record lows,\" adding that margins have improved so far in Q1 but \"have further to go to restore profitability.\"</li><li>Q4 production gallons sold fell 13% Y/Y to 131.1M and total gallons sold also slid 13% to 209.4M; the company's average ethanol sales price averaged $1.45/gal vs. $1.52/gal in the year-ago quarter.</li><li>The company says it has initiated a strategic realignment to improve liquidity  and reduce debt but provides no specifics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442374\" data-linked=\"Pacific Ethanol -2% as Q4 loss more than doubles\" data-tweet=\"$PEIX - Pacific Ethanol -2% as Q4 loss more than doubles https://seekingalpha.com/news/3442374-pacific-ethanolminus-2-q4-loss-doubles?source=tweet\" data-url=\"https://seekingalpha.com/news/3442374-pacific-ethanolminus-2-q4-loss-doubles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442371\" data-ts=\"1552494687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APEI\" target=\"_blank\">APEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442371-american-public-educationplus-3_4-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Public Education +3.4% post Q4 results</a></h4><ul><li>American Public Education (<a href='https://seekingalpha.com/symbol/APEI' title='American Public Education, Inc.'>APEI</a> <font color=\"green\">+3.4%</font>) reports <a href=\"https://seekingalpha.com/pr/17441947-american-public-education-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Q4</a> revenue decrease of 1.5% Y/Y to $73.93M.</li><li>Net course registrations at APUS declined by 1% Y/Y to 79,400.</li><li>Net course registrations by new students decreased by ~1% Y/Y to 9,800.</li><li>APUS student enrollment decreased by 2% Y/Y to ~81,400 students.</li><li>New student enrollment at HCN decreased by ~4% Y/Y.</li><li>Total student enrollment at HCN was flat Y/Y.</li><li>Total cash and equivalents were ~$212.1M &amp; Capex were ~$9.4M.</li><li><b>1Q19 Outlook:</b> Decrease in revenues of 5%-0% Y/Y; EPS of $0.29-0.34; At APUS, net course registrations by new students expected to increase 8% Y/Y; At HCN, new student enrollment decreased ~30% Y/Y and total student enrollment decrease ~15% Y/Y.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442035-american-public-education-beats-revenue\" target=\"_blank\">American Public Education beats on revenue</a> (Mar. 12 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442371\" data-linked=\"American Public Education +3.4% post Q4 results\" data-tweet=\"$APEI - American Public Education +3.4% post Q4 results https://seekingalpha.com/news/3442371-american-public-educationplus-3_4-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3442371-american-public-educationplus-3_4-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442370\" data-ts=\"1552494673\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENC\" target=\"_blank\">FENC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442370-fennec-pharma-down-9-on-pedmark-filing-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fennec Pharma down 9% on Pedmark filing delay</a></h4><ul><li>Thinly traded micro cap Fennec Pharmaceuticals (<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals Inc.'>FENC</a> <font color=\"red\">-9.3%</font>) is down on more than 70% higher volume, albeit on turnover of only 94K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17442352-fennec-provides-business-update-announces-fiscal-year-2018-financial-results\" target=\"_blank\">announcement </a>that it now expects to complete the rolling submission of its U.S. marketing application for lead candidate PEDMARK near year-end or early 2020, a delay of six months or more.</li><li>The company had already started the process, but its contract ingredient manufacturer was acquired which necessitated a facility change.</li><li><a href=\"https://fennecpharma.com/product-candidates/sts/\" target=\"_blank\">PEDMARK</a>, a novel formulation of chemical reducing agent sodium thiosulfate, will be used to prevent hearing damage in pediatric cancer patients receiving platinum-based chemo.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442370\" data-linked=\"Fennec Pharma down 9% on Pedmark filing delay\" data-tweet=\"$FENC - Fennec Pharma down 9% on Pedmark filing delay https://seekingalpha.com/news/3442370-fennec-pharma-down-9-on-pedmark-filing-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3442370-fennec-pharma-down-9-on-pedmark-filing-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442364\" data-ts=\"1552493088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442364-vera-bradley-and-westport-fuel-systems-among-consumer-gainers-clearwater-paper-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley and Westport Fuel Systems among consumer gainers; Clearwater Paper leads the losers</a></h4><ul><li><b>Gainers: </b>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>) <font color=\"green\">+20%</font>. Ballantyne Strong (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc'>BTN</a>) <font color=\"green\">+13%</font>. Limoneira (NASDAQ:<a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira Company'>LMNR</a>) <font color=\"green\">+12%</font>. Westport Fuel Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems Inc.'>WPRT</a>) <font color=\"green\">+9%</font>. YETI Holdings (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='YETI Holdings, Inc.'>YETI</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Clearwater Paper (NYSE:<a href='https://seekingalpha.com/symbol/CLW' title='Clearwater Paper Corporation'>CLW</a>) <font color=\"red\">-15%</font>. Coffee Holding Co (NASDAQ:<a href='https://seekingalpha.com/symbol/JVA' title='Coffee Holding Co., Inc.'>JVA</a>) <font color=\"red\">-10%</font>. Mannatech (NASDAQ:<a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442364\" data-linked=\"Vera Bradley and Westport Fuel Systems among consumer gainers; Clearwater Paper leads the losers\" data-tweet=\"$VRA $BTN $LMNR - Vera Bradley and Westport Fuel Systems among consumer gainers; Clearwater Paper leads the losers https://seekingalpha.com/news/3442364-vera-bradley-and-westport-fuel-systems-among-consumer-gainers-clearwater-paper-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442364-vera-bradley-and-westport-fuel-systems-among-consumer-gainers-clearwater-paper-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442363\" data-ts=\"1552493061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEN\" target=\"_blank\">SIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442363-sientra-q4-miss-pressures-shares-down-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sientra Q4 miss pressures shares, down 25%</a></h4><ul><li>Sientra (<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a> <font color=\"red\">-25.4%</font>) slumps on more than 6x normal volume following its <a href=\"https://seekingalpha.com/news/3442000-sientra-misses-0_18-beats-revenue\" target=\"_blank\">Q4 and 2018 report</a> released after the close yesterday.</li><li>Q4 sales jumped 72% to $19.0M, but net loss was ($24.6M)($0.86/share), wider than consensus of ($0.68).</li><li>Breast Products sales were $10.4M (+28%).</li><li>Cash and equivalents at year-end were $86.9M, down $16.1M from Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442363\" data-linked=\"Sientra Q4 miss pressures shares, down 25%\" data-tweet=\"$SIEN - Sientra Q4 miss pressures shares, down 25% https://seekingalpha.com/news/3442363-sientra-q4-miss-pressures-shares-down-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3442363-sientra-q4-miss-pressures-shares-down-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442361\" data-ts=\"1552492475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442361-trading-surge-in-oil-options-prompts-speculation-around-petrobras-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading surge in oil options prompts speculation around Petrobras - Bloomberg</a></h4><ul><li>Global oil options markets this week are the <a href=\"https://www.bloomberg.com/news/articles/2019-03-13/oil-options-trading-jumps-as-large-producer-is-said-to-hedge\" target=\"_blank\">busiest since November</a>  amid a flurry of buying apparently from a large producer  protecting against a drop in prices, Bloomberg reports.</li><li>Some traders reportedly have pointed to Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petróleo Brasileiro S.A. - Petrobras'>PBR</a> <font color='green'>+1.6%</font>) as the buyer, given the timing and size of the  trades; the company said in a 2018 filing that it hedged 128M barrels of crude at an average price of $65/bbl, buying the  protection in February and March.</li><li>CEO Roberto Castello Branco said over the weekend that the company's best protection  against periods of low prices in the international market is low  production costs but it is also willing to continue to use hedging  instruments to protect part of the production from price variations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442361\" data-linked=\"Trading surge in oil options prompts speculation around Petrobras - Bloomberg\" data-tweet=\"$PBR - Trading surge in oil options prompts speculation around Petrobras - Bloomberg https://seekingalpha.com/news/3442361-trading-surge-in-oil-options-prompts-speculation-around-petrobras-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3442361-trading-surge-in-oil-options-prompts-speculation-around-petrobras-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442356\" data-ts=\"1552491852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BP\" target=\"_blank\">BP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442356-bp-teams-up-environmental-defense-fund-to-combat-methane-leaks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BP teams up with Environmental Defense Fund to combat methane leaks</a></h4><ul><li>BP (<a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> <font color=\"green\">+2.6%</font>) joins Royal Dutch Shell in <a href=\"https://uk.reuters.com/article/us-ceraweek-energy-bp-methane/bp-teams-up-with-edf-to-tackle-methane-leaks-idUKKBN1QU1IB\" target=\"_blank\">urging the U.S. government</a> to tighten rules limiting methane leaks from oil and gas production and says it is teaming up with a prominent  environmental group to develop technologies to limit emissions of the  greenhouse gas.</li><li>\"We believe in direct federal regulation of methane for new and existing  sources\" in the U.S., Bernard Looney, head of BP oil and  gas production, said yesterday at the CERAWeek energy conference in  Houston.</li><li>CEO Bob Dudley said the continued persistence of fossil fuels means the world is  not on a \"sustainable path\" to avoid the worst harms of global warming.</li><li>Shell <a href=\"https://seekingalpha.com/news/3441971-shell-exec-urges-u-s-tighten-methane-leak-rules\" target=\"_blank\">yesterday</a> prodded the Trump administration to tighten restrictions on methane gas emissions.</li><li>BP aimed to cut methane emissions to 0.2% of its overall oil  and gas output by 2025, and Looney said the company achieved that target in 2018.</li><li>BP also announced a three-year partnership with the  Environmental Defense Fund aimed at developing further technologies  to detect and prevent methane leaks.</li><li>If all energy companies achieved methane emission targets similar to BP,  it would equal shutting ~2K big coal-fired power  plants, according to EDF President Fred Krupp.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442356\" data-linked=\"BP teams up with Environmental Defense Fund to combat methane leaks\" data-tweet=\"$BP - BP teams up with Environmental Defense Fund to combat methane leaks https://seekingalpha.com/news/3442356-bp-teams-up-environmental-defense-fund-to-combat-methane-leaks?source=tweet\" data-url=\"https://seekingalpha.com/news/3442356-bp-teams-up-environmental-defense-fund-to-combat-methane-leaks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442354\" data-ts=\"1552491731\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMLFF\" target=\"_blank\">IMLFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442354-inmed-pharma-pivots-to-single-agent-cannabinoid-for-rare-skin-disorder-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2%</a></h4><ul><li>Citing a greater likelihood of success, InMed Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IMLFF' title='InMed Pharmaceuticals Inc.'>OTCQX:IMLFF</a> <font color=\"green\">+2.3%</font>) has dropped its two-cannabinoid combo, INM-750, in favor of a <a href=\"https://seekingalpha.com/pr/17442474-inmed-pharmaceuticals-announces-transition-single-cannabinoid-investigational-drug-candidate\" target=\"_blank\">single cannabinoid approach</a>, designated as INM-755, for the potential treatment of <a href=\"https://ghr.nlm.nih.gov/condition/dystrophic-epidermolysis-bullosa\" target=\"_blank\">epidermolysis bullosa</a>, a rare inherited skin disorder characterized by blisters and erosions from minor injury, rubbing or scratching.</li><li>A Phase 1 study should launch by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442354\" data-linked=\"InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2%\" data-tweet=\"$IMLFF - InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2% https://seekingalpha.com/news/3442354-inmed-pharma-pivots-to-single-agent-cannabinoid-for-rare-skin-disorder-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3442354-inmed-pharma-pivots-to-single-agent-cannabinoid-for-rare-skin-disorder-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442353\" data-ts=\"1552491448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CACI\" target=\"_blank\">CACI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442353-caciplus-2-on-top-pick-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CACI +2% on Top Pick upgrade</a></h4><ul><li>Vertical Research Partners upgrades CACI (NYSE:<a href='https://seekingalpha.com/symbol/CACI' title='CACI International Inc'>CACI</a>) from Buy to Top Pick with a $228 target, up from $212 and implying a 26% upside.</li><li>CACI replaces previous Top Pick Leidos (<a href='https://seekingalpha.com/symbol/LDOS' title='Leidos Holdings, Inc.'>LDOS</a> <font color='green'>+0.6%</font>).</li><li>In January, CACI reported Q2 results that beat EPS estimates and <a href=\"https://seekingalpha.com/news/3428223-caci-international-q2-performance-raises-fy19-outlook\" target=\"_blank\">raised</a> its FY19 outlook.</li><li>CACI shares are <font color=\"green\">up 2.1%</font> to $184.22.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442353\" data-linked=\"CACI +2% on Top Pick upgrade\" data-tweet=\"$CACI $CACI $LDOS - CACI +2% on Top Pick upgrade https://seekingalpha.com/news/3442353-caciplus-2-on-top-pick-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3442353-caciplus-2-on-top-pick-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442351\" data-ts=\"1552491266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TISI\" target=\"_blank\">TISI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442351-team-up-10-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Team up 10% post Q4 results</a></h4><ul><li>Team (<a href='https://seekingalpha.com/symbol/TISI' title='Team, Inc.'>TISI</a> <font color=\"green\">+10.6%</font>) Q4 revenue decreased by 2.1% Y/Y to $309.8M. Segment revenues: IHT $149.76M (+0.7% Y/Y); MS $131.47M (-9.2% Y/Y); and Quest Integrity $28.57M (+25.2% Y/Y).</li><li>Q4 Gross margin <font color=\"green\">improved by 177 bps</font> to 27.6%.</li><li>Adj. EBIT was $5.29M (-33.1% Y/Y) and margin <font color=\"red\">declined by 80 bps</font> to 1.7%.</li><li>Adj. EBITDA was $24.54M (+4.8% Y/Y) and margin <font color=\"green\">improved by 52 bps </font>to 7.9%.</li><li>SG&amp;A expenses were $90.07M (+8.7% Y/Y) and margin was 29.1% <font color=\"red\">up by 289 bps</font>.</li><li>Q4 Operating cash flow of $36.6M, and Free cash flow for the quarter was $28.79M, compared to negative $13.82M a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442133-team-reports-q4-results\" target=\"_blank\">Team reports Q4 results</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442351\" data-linked=\"Team up 10% post Q4 results\" data-tweet=\"$TISI - Team up 10% post Q4 results https://seekingalpha.com/news/3442351-team-up-10-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3442351-team-up-10-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442349\" data-ts=\"1552490839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACB\" target=\"_blank\">ACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442349-peltz-can-solve-biggest-problem-aurora-cannabis-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peltz can solve biggest problem at Aurora Cannabis - Jefferies</a></h4><ul><li>Jefferies analyst Owen Bennett says strategic advisor Nelson Peltz, with his skills maximizing profits and efficient asset allocation, can <a href=\"https://www.businessinsider.com/weed-aurora-cannabis-stock-price-solving-problem-with-the-help-of-nelson-peltz-2019-3\" target=\"_blank\">solve the biggest problem</a> at Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"green\">+11%</font>), achieving profitable growth.</li><li>Some investors have criticized the company for spending large amounts of money on a range of assets across its value chain with scant results to date.</li><li>In <a href=\"https://seekingalpha.com/news/3432027-aurora-cannabis-3-percent-q2-results\" target=\"_blank\">fiscal Q2</a>, the company's gross margin contracted almost 23% to 54% due to higher production costs. Net loss was (C$238M).</li></ul><div class=\"tiny-share-widget\" data-id=\"3442349\" data-linked=\"Peltz can solve biggest problem at Aurora Cannabis - Jefferies\" data-tweet=\"$ACB - Peltz can solve biggest problem at Aurora Cannabis - Jefferies https://seekingalpha.com/news/3442349-peltz-can-solve-biggest-problem-aurora-cannabis-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3442349-peltz-can-solve-biggest-problem-aurora-cannabis-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>154&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442348\" data-ts=\"1552490815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442348-t-confirms-directv-now-changes-viacom-discovery-amc-tumble\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AT&amp;T confirms DirecTV Now changes; Viacom, Discovery, AMC tumble</a></h4><ul>   <li>AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"red\">-1%</font>) has confirmed <a href=\"https://seekingalpha.com/news/3442041-t-readies-slimmer-streaming-live-tv-packages\" target=\"_blank\">heavy changes</a> to its DirecTV Now streaming service, The Verge notes, with added HBO but higher prices and the <a href=\"https://www.theverge.com/2019/3/13/18263839/att-directv-now-2019-channel-changes-hbo-plan-price\" target=\"_blank\">removal of several popular channels</a> for new subscribers.</li>    <li>The company announced yesterday it was readying two bundles for launch at $50/month and $70/month. But the $50 plan is now the most expensive base plan of the five rivals in the streaming live TV space (which includes Hulu with Live TV, PlayStation Vue (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color=\"green\">+1%</font>), Sling TV (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"red\">-0.3%</font>) and YouTube TV (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color=\"green\">+0.4%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color=\"green\">+0.7%</font>)).</li>    <li>And while the company's adding HBO to the new plans, it's dropping channels from AMC Networks (<a href=\"http://seekingalpha.com/symbol/AMCX\" target=\"_blank\">AMCX</a> <font color=\"red\">-3.3%</font>), Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color=\"red\">-1.4%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color=\"red\">-2.2%</font>) and Discovery (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color=\"red\">-2.3%</font>), including HGTV, A&amp;E, MTV, TLC and Nickelodeon, among others. Shares in those companies are dropping quickly.</li>    <li>Existing customers will be able to keep their current plans, but those with HBO will need to pay $15/month now rather than $5/month, a move that will serve to push them to one of the two new offerings.</li>    <li>Of the five streaming-live TV rivals, only Sling continues to offer the Viacom networks.</li><li>Hulu, for now, is co-owned by Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>), Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>), Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>) and AT&amp;T's WarnerMedia.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442348\" data-linked=\"AT&amp;T confirms DirecTV Now changes; Viacom, Discovery, AMC tumble\" data-tweet=\"$GOOG $GOOGL $VIA - AT&amp;T confirms DirecTV Now changes; Viacom, Discovery, AMC tumble https://seekingalpha.com/news/3442348-t-confirms-directv-now-changes-viacom-discovery-amc-tumble?source=tweet\" data-url=\"https://seekingalpha.com/news/3442348-t-confirms-directv-now-changes-viacom-discovery-amc-tumble\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>178&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442346\" data-ts=\"1552490214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRP\" target=\"_blank\">NTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442346-neurotrope-completes-enrollment-in-mid-stage-study-of-bryostatinminus-1-in-alzheimers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neurotrope completes enrollment in mid-stage study of Bryostatin-1 in Alzheimer&#39;s</a></h4><ul><li>Neurotrope (<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a> <font color=\"red\">-3%</font>) has <a href=\"https://seekingalpha.com/pr/17442655-neurotrope-completes-enrollment-confirmatory-phase-2-study-bryostatinminus-1-moderate-severe\" target=\"_blank\">completed the enrollment</a> of 108 subjects in its confirmatory <a href=\"https://clinicaltrials.gov/ct2/show/NCT03560245?lead=neurotrope&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating Bryostatin-1 in patients with moderate-to-severe Alzheimer's disease who are not on memantine.</li><li>The primary efficacy endpoint is the change in Severe Impairment Battery &#40;SIB&#41; score from baseline. Topline results should be available in H2.</li><li><a href=\"http://www.brni.org/scientific_research/clinical_trials.aspx\" target=\"_blank\">Bryostatin</a>, an activator of protein kinase &#40;PKC&#41;, was originally developed as a cancer chemotherapeutic.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442346\" data-linked=\"Neurotrope completes enrollment in mid-stage study of Bryostatin-1 in Alzheimer&#39;s\" data-tweet=\"$NTRP - Neurotrope completes enrollment in mid-stage study of Bryostatin-1 in Alzheimer&#39;s https://seekingalpha.com/news/3442346-neurotrope-completes-enrollment-in-mid-stage-study-of-bryostatinminus-1-in-alzheimers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442346-neurotrope-completes-enrollment-in-mid-stage-study-of-bryostatinminus-1-in-alzheimers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442344\" data-ts=\"1552490035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLFC\" target=\"_blank\">WLFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442344-willis-lease-financeplus-5_6-revenue-jumps-87\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Willis Lease Finance +5.6% as revenue jumps 87%</a></h4><ul><li>Willis Lease Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/WLFC' title='Willis Lease Finance Corporation'>WLFC</a>) <font color=\"green\">gains 5.6%</font> after<a href=\"https://seekingalpha.com/pr/17442300-willis-lease-finance-corporation-reports-record-annual-pre-tax-profit-56_3-million\" target=\"_blank\"> Q4 total revenue</a> jumped 87% to $118.2M from $63.2M a year earlier.</li><li>Included in Q4 2018 total revenue was $5.3M gain on sale of leased equipment; adoption of ASC 606 accounting standard as of Jan. 1, 2018 increased spare parts and equipment sales revenue by $1.9M and cut the gain on sale of leased equipment by $0.2M during the quarter.</li><li>Q4 earnings from operations increased to $19.6M from $2.09M a year earlier.</li><li>Book value per share increased to $47.43 at Dec. 31, 2018 from $41.63 at Dec. 31, 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3404988-willis-lease-finance-reports-q3-results\" target=\"_blank\">Willis Lease Finance reports Q3 results</a> (Nov. 5, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442344\" data-linked=\"Willis Lease Finance +5.6% as revenue jumps 87%\" data-tweet=\"$WLFC - Willis Lease Finance +5.6% as revenue jumps 87% https://seekingalpha.com/news/3442344-willis-lease-financeplus-5_6-revenue-jumps-87?source=tweet\" data-url=\"https://seekingalpha.com/news/3442344-willis-lease-financeplus-5_6-revenue-jumps-87\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442340\" data-ts=\"1552489652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVNA\" target=\"_blank\">CVNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442340-carvana-pushes-higher-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carvana pushes higher again</a></h4><ul><li>Carvana (<a href='https://seekingalpha.com/symbol/CVNA' title='Carvana Co.'>CVNA</a> <font color='green'>+6.3%</font>) rallies after Wolfe Research back up its bullish view on the online auto retailer.</li><li>The firm points to a due diligence report filed by Carvana on its ABS.</li><li>Last week, it was a report on an acceleration of Carvana retail orders that sparked some buying action.</li><li>Shares of Carvana are now up 72% YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442340\" data-linked=\"Carvana pushes higher again\" data-tweet=\"$CVNA - Carvana pushes higher again https://seekingalpha.com/news/3442340-carvana-pushes-higher-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3442340-carvana-pushes-higher-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442335\" data-ts=\"1552489285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442335-insys-continues-selloff-from-near-term-rally-down-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSYS continues selloff from near-term rally, down 12%</a></h4><ul><li>INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='INSYS Therapeutics, Inc.'>INSY</a> <font color=\"red\">-11.6%</font>) is down on modestly higher volume. Shares have sold off more than <font color=\"red\">21%</font> since touching $6.59 on March 4. The stock had rallied over <font color=\"green\">80%</font> in February before correcting.</li><li>It filed its 2018 annual report yesterday evening. Sales were down 42%, primarily due to continued pressure on Subsys.</li><li>Operations consumed $55.9M during the year. Quick assets totaled $95.7M at year-end.</li><li>The <a href=\"https://www.sec.gov/Archives/edgar/data/1516479/000156459019007444/insy-10k_20181231.htm\" target=\"_blank\">10-K</a> includes a disclosure (page 94) that the company will require significant additional capital which may be difficult to raise, therefore creating \"substantial doubt\" about its ability to survive considering its legal expenses. Management is exploring strategic alternatives in order to meet its obligations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442335\" data-linked=\"INSYS continues selloff from near-term rally, down 12%\" data-tweet=\"$INSY $INSYQ - INSYS continues selloff from near-term rally, down 12% https://seekingalpha.com/news/3442335-insys-continues-selloff-from-near-term-rally-down-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3442335-insys-continues-selloff-from-near-term-rally-down-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442334\" data-ts=\"1552489243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442334-akari-therapeutics-leads-healthcare-gainers-verastem-and-seelos-therapeutics-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari Therapeutics leads healthcare gainers; Verastem and Seelos Therapeutics among losers</a></h4><ul><li><b>Gainers: </b>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+157%</font>. Natera (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRA' title='Natera, Inc.'>NTRA</a>) <font color=\"green\">+22%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"green\">+15%</font>. Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics, Inc.'>ALRN</a>) <font color=\"green\">+15%</font>. Guardant Health (NASDAQ:<a href='https://seekingalpha.com/symbol/GH' title='Guardant Health, Inc.'>GH</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>Sientra (NASDAQ:<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra, Inc.'>SIEN</a>) <font color=\"red\">-25%</font>. Amphastar Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar Pharmaceuticals, Inc.'>AMPH</a>) <font color=\"red\">-14%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics, Inc.'>SEEL</a>) <font color=\"red\">-11%</font>. Lipocine (NASDAQ:<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a>) <font color=\"red\">-10%</font>. Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442334\" data-linked=\"Akari Therapeutics leads healthcare gainers; Verastem and Seelos Therapeutics among losers\" data-tweet=\"$AKTX $NTRA $DFFN - Akari Therapeutics leads healthcare gainers; Verastem and Seelos Therapeutics among losers https://seekingalpha.com/news/3442334-akari-therapeutics-leads-healthcare-gainers-verastem-and-seelos-therapeutics-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442334-akari-therapeutics-leads-healthcare-gainers-verastem-and-seelos-therapeutics-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442328\" data-ts=\"1552488861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYD\" target=\"_blank\">BYD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442328-boyd-gains-on-new-sports-betting-location\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boyd gains on new sports betting location</a></h4><ul><li>Boyd Gaming (<a href='https://seekingalpha.com/symbol/BYD' title='Boyd Gaming Corporation'>BYD</a> <font color='green'>+1.1%</font>) and FanDuel Group <a href=\"https://seekingalpha.com/pr/17443026-fanduel-group-boyd-gaming-announce-grand-opening-fanduel-sportsbook-valley-forge-casino\" target=\"_blank\">announce</a> the grand opening of the FanDuel Sportsbook at the Valley Forge Casino Resort, marking the first Sportsbook in Pennsylvania.</li><li>The 1,800 square foot sports betting location contains seven teller windows, 29 video displays, two sports tickers, and seating for over 30 customers.</li><li>The new Sportsbook location opens today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442328\" data-linked=\"Boyd gains on new sports betting location\" data-tweet=\"$BYD - Boyd gains on new sports betting location https://seekingalpha.com/news/3442328-boyd-gains-on-new-sports-betting-location?source=tweet\" data-url=\"https://seekingalpha.com/news/3442328-boyd-gains-on-new-sports-betting-location\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442327\" data-ts=\"1552488733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GV\" target=\"_blank\">GV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442327-on-goldfields-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Goldfield&#39;s Q4 results</a></h4><ul><li>Goldfield (<a href='https://seekingalpha.com/symbol/GV' title='The Goldfield Corporation'>GV</a> <font color=\"red\">-2.8%</font>) reported Q4 revenue growth of 23.9% Y/Y to $36.69M, due to the increase in electrical construction operations.</li><li>Segment revenues: Electrical construction $36.68M (+34.5% Y/Y) and Real estate development $2.3M (-99.9% Y/Y), decrease in revenue was due to the reduced number of completed units available for sale through year-end.</li><li>Electrical construction gross margin <font color=\"red\">declined by 230 bps</font> to 13.4%, reflecting the decline in the number of completed units available for sale through year-end</li><li>Q4 operating margin declined by 318 bps to 2.3%.</li><li>EBITDA was $3.31M (+3.03% Y/Y) and margin <font color=\"red\">declined by 182 bps</font> to 9%.</li><li>Total Backlog was of $214.5M flat, with Electrical construction backlog at $101.8M (-7.6% YY).</li><li>Company extended its Stock Repurchase plan from September 30, 2019 until September 30, 2020 and increased the number of shares available for purchase. The revised plan will permit an additional 2,500,000 shares to be repurchased, increasing the amount available for repurchase to 2,726,120 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442071-goldfield-reports-q4-results\" target=\"_blank\">Goldfield reports Q4 results</a> (March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442327\" data-linked=\"More on Goldfield&#39;s Q4 results\" data-tweet=\"$GV - More on Goldfield&#39;s Q4 results https://seekingalpha.com/news/3442327-on-goldfields-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3442327-on-goldfields-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442310\" data-ts=\"1552487998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEB\" target=\"_blank\">HEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442310-hemispherx-bio-up-8-on-ampligen-progress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hemispherx Bio up 8% on Ampligen progress</a></h4><ul><li>Nano cap Hemispherx Biopharma (<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a> <font color=\"green\">+7.5%</font>) is up on more than triple normal volume following its <a href=\"https://seekingalpha.com/pr/17442869-hemispherx-biopharma-announces-significant-progress-ampligen-pancreatic-cancer-program\" target=\"_blank\">update</a> on its Ampligen programs. It plans to release additional updates on a quarterly basis.</li><li>Multiple clinical trials are in process at the Roswell Park Comprehensive Cancer Center and the University of Pittsburgh Medical Center. Two new studies assessing the combination of Ampligen and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"green\">+0.2%</font>) Keytruda (pembrolizumab) have been initiated at both sites.</li><li>Five additional trials evaluating combinations of Ampligen and various checkpoint inhibitors are being prepared.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442310\" data-linked=\"Hemispherx Bio up 8% on Ampligen progress\" data-tweet=\"$HEB $MRK $AIM - Hemispherx Bio up 8% on Ampligen progress https://seekingalpha.com/news/3442310-hemispherx-bio-up-8-on-ampligen-progress?source=tweet\" data-url=\"https://seekingalpha.com/news/3442310-hemispherx-bio-up-8-on-ampligen-progress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442319\" data-ts=\"1552487466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442319-crude-inventory-unexpectedly-falls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory unexpectedly falls</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-3.9</strong><strong>M</strong> barrels vs. +2.7M consensus, +7.1M last week.</li><li>Gasoline <strong>-4.6M</strong> barrels vs. -2.5M consensus, -4.2M last week.</li><li>Distillates <strong>+0.4M</strong> barrels vs. -1.9M consensus, -2.4M last week.</li><li>Futures <font color=\"green\">+1.6%</font> to $57.78.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442319\" data-linked=\"Crude inventory unexpectedly falls\" data-tweet=\"$USO $OIL $UCO - Crude inventory unexpectedly falls https://seekingalpha.com/news/3442319-crude-inventory-unexpectedly-falls?source=tweet\" data-url=\"https://seekingalpha.com/news/3442319-crude-inventory-unexpectedly-falls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442304\" data-ts=\"1552485680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLNE\" target=\"_blank\">CLNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442304-clean-energy-fuelsplus-23-after-q4-easily-tops-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clean Energy Fuels +23% after Q4 easily tops expectations</a></h4><ul><li>Clean Energy Fuels (<a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a> <font color='green'>+23.8%</font>) surges in early trading after reporting a smaller than expected <a href=\"https://seekingalpha.com/news/3442006-clean-energy-fuels-beats-0_03-beats-revenue\" target=\"_blank\">Q4 loss</a> and better than expected revenues of $96.2M, up from $89.3M in the year-earlier quarter.</li><li>CLNE says it delivered 98.7M gallons in Q4, 14.2% above the 86.4M gallons delivered in the year-ago       quarter; for the full yea, it delivered 365.5M gallons, up 4% from       351.4M gallons delivered during 2017.</li><li>CLNE forecasts a FY 2019 GAAP net loss of $12M-$18M and adjusted EBITDA of $50M-$55M, assuming no AFTC; the company says legislative       circumstances impacting the AFTC and changes in diesel and natural gas       market conditions resulting in unrealized gains or losses on commodity swap contracts could significantly impact results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442304\" data-linked=\"Clean Energy Fuels +23% after Q4 easily tops expectations\" data-tweet=\"$CLNE - Clean Energy Fuels +23% after Q4 easily tops expectations https://seekingalpha.com/news/3442304-clean-energy-fuelsplus-23-after-q4-easily-tops-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3442304-clean-energy-fuelsplus-23-after-q4-easily-tops-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442299\" data-ts=\"1552485495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCAU\" target=\"_blank\">FCAU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442299-fiat-lower-on-report-of-u-s-recall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fiat lower on report of U.S. recall</a></h4><ul> <li>Fiat Chrysler Automobiles (<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles N.V.'>FCAU</a> <font color='red'>-0.9%</font>) is lower after Reuters reports the automaker will recall 862,520 cars in the U.S. that don't meet emissions standards.</li><li>The post will be updated with recall details when they are available.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3442299\" data-linked=\"Fiat lower on report of U.S. recall\" data-tweet=\"$FCAU - Fiat lower on report of U.S. recall https://seekingalpha.com/news/3442299-fiat-lower-on-report-of-u-s-recall?source=tweet\" data-url=\"https://seekingalpha.com/news/3442299-fiat-lower-on-report-of-u-s-recall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442297\" data-ts=\"1552485366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRTC\" target=\"_blank\">IRTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442297-kerrisdale-bearish-on-irhythm-tech-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kerrisdale bearish on iRhythm Tech; shares down 3%</a></h4><ul><li>IRhythm Technologies (<a href='https://seekingalpha.com/symbol/IRTC' title='iRhythm Technologies, Inc.'>IRTC</a> <font color=\"red\">-2.6%</font>) is down on modestly higher volume in early trade in apparent response to a <a href=\"https://www.kerrisdalecap.com/wp-content/uploads/2019/03/iRhythm-Technologies-Inc.-IRTC.pdf\" target=\"_blank\">bearish report</a> from Kerrisdale Capital who is short the stock. Key points:</li><li>Revenue growth for the Zio heart rate monitor patch will dramatically fall in the coming years due to expected lower reimbursement. Heretofore, the company has been able to secure revenues higher than legacy cardiac monitoring methods due to \"skillful maneuvering\" around the reimbursement coding process. Zio's temporary CPT code will transition to a permanent code in 2021, a move that could slice reimbursement by 33 - 50%.</li><li>Competition is heating up with new entrants offering superior devices and more diverse product portfolios. IRTC's efforts to diversify have fallen flat, evidenced by its pullback on the Zio AT device.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442297\" data-linked=\"Kerrisdale bearish on iRhythm Tech; shares down 3%\" data-tweet=\"$IRTC - Kerrisdale bearish on iRhythm Tech; shares down 3% https://seekingalpha.com/news/3442297-kerrisdale-bearish-on-irhythm-tech-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3442297-kerrisdale-bearish-on-irhythm-tech-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442292\" data-ts=\"1552485029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MELI\" target=\"_blank\">MELI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442292-mercadolibreplus-3-after-pt-lift-secondary-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MercadoLibre +3% after PT lift, secondary pricing</a></h4><ul> <li>MercadoLibre (NASDAQ:<a href='https://seekingalpha.com/symbol/MELI' title='MercadoLibre, Inc.'>MELI</a>) is higher after landing a price target increase from BTIG and reporting that it priced its $1B follow-on offering at $480 per share.</li>  <li>Shares of MercadoLibre are <font color=\"green\">up 3.12%</font> to $498.57</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442292\" data-linked=\"MercadoLibre +3% after PT lift, secondary pricing\" data-tweet=\"$MELI - MercadoLibre +3% after PT lift, secondary pricing https://seekingalpha.com/news/3442292-mercadolibreplus-3-after-pt-lift-secondary-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3442292-mercadolibreplus-3-after-pt-lift-secondary-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442286\" data-ts=\"1552484248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442286-akari-up-15-on-fda-nod-on-trial-design-for-coversin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari up 15% on FDA nod on trial design for Coversin</a></h4><ul><li>Thinly traded nano cap Akari Therapeutics (<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a> <font color=\"green\">+15.4%</font>) is up out of the gate this morning following its <a href=\"https://seekingalpha.com/pr/17442685-positive-fda-meeting-outlines-path-ahead-akari-therapeutics-s-coversin-hematopoietic-stem\" target=\"_blank\">announcement </a>that the FDA has signed off on the endpoints for a pivotal study evaluating second-generation complement inhibitor Coversin for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), a disorder with a mortality rate of more than 80%.</li><li>The endpoint will be clinically meaningful treatment variables, including markers of complement activation and markers that are elevated in thrombotic microangiopathy like platelet count, red blood cell fragments, thrombocytopenia, elevated LDH (enzyme) and hypertension.</li><li>The study should launch in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442286\" data-linked=\"Akari up 15% on FDA nod on trial design for Coversin\" data-tweet=\"$AKTX - Akari up 15% on FDA nod on trial design for Coversin https://seekingalpha.com/news/3442286-akari-up-15-on-fda-nod-on-trial-design-for-coversin?source=tweet\" data-url=\"https://seekingalpha.com/news/3442286-akari-up-15-on-fda-nod-on-trial-design-for-coversin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442281\" data-ts=\"1552483517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGLB\" target=\"_blank\">SGLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442281-sigma-labsminus-6-on-public-offering-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sigma Labs -6% on public offering pricing</a></h4><ul><li>Sigma Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a>) <a href=\"https://seekingalpha.com/pr/17442744-sigma-labs-inc-announces-pricing-public-offering-1400-800-units\" target=\"_blank\">prices</a> its previously announced public offering of common stock and warrants with anticipated gross proceeds of over $1.96M.</li><li>The offering has 1,400,800 units that each include one share of common stock and 30% of a warrant to buy a share at $1.40 per unit. The warrants are immediately executable at $1.61 per share.</li><li>The offering is expected to close on or about March 15.</li><li>Sigma Labs shares are <font color=\"red\">down 6.3%</font> pre-market to $1.48.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442281\" data-linked=\"Sigma Labs -6% on public offering pricing\" data-tweet=\"$SGLB - Sigma Labs -6% on public offering pricing https://seekingalpha.com/news/3442281-sigma-labsminus-6-on-public-offering-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3442281-sigma-labsminus-6-on-public-offering-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442274\" data-ts=\"1552483267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MO\" target=\"_blank\">MO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442274-fda-draft-guidance-on-e-cigs-includes-tighter-restrictions-on-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA draft guidance on e-cigs includes tighter restrictions on sales</a></h4><ul><li>The FDA released its <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633291.htm\" target=\"_blank\">draft guidance</a> today for e-cigarettes aimed at curbing use, especially among young people. The public comment period is 30 days.</li><li>The plan includes new restrictions on most flavored e-cigs, a quicker deadline to review flavored nicotine products and the ability for the agency to pull e-cigs from the market. If enacted, the new policy will likely remove some flavored e-cigs and cigars from retail stores.</li><li>Sales of flavored nicotine pods will be restricted to websites, vape shops and other retailers that impose age restrictions.</li><li>The agency will crack down on kid-enticing offerings, such as packaging designed to mimic juice boxes or candy.</li><li>The deadline for manufacturers to submit marketing applications for most flavored e-cigs will be moved up a year to August 8, 2021. The changes do not apply to menthol, mint and tobacco, flavors that the agency want to preserve since they are available in cigarettes and help switch adult smokers.</li><li>Flavored cigars introduced after 2016 without the FDA's nod will be subject to new enforcement actions, including possible withdrawal from the market.</li><li>Selected tickers: Altria Group (NYSE:<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a>)(down a fraction); British American Tobacco (NYSE:<a href='https://seekingalpha.com/symbol/BTI' title='British American Tobacco p.l.c.'>BTI</a>)(<font color=\"red\">-2%</font>); Vape Holdings (<a href='https://seekingalpha.com/symbol/VAPE' title='Vape Holdings, Inc.'>OTCPK:VAPE</a>); Hop-On (<a href='https://seekingalpha.com/symbol/HPNN' title='Hop-On Inc.'>OTCPK:HPNN</a>); mCIG (<a href='https://seekingalpha.com/symbol/MCIG' title='mCig, Inc.'>OTCPK:MCIG</a>); Neutra (<a href='https://seekingalpha.com/symbol/NTRR' title='Neutra Corp.'>OTCQB:NTRR</a>); VaporBrands International (<a href='https://seekingalpha.com/symbol/VAPR' title='VaporBrands International, Inc.'>OTCPK:VAPR</a>); American Heritage International (<a href='https://seekingalpha.com/symbol/AHII' title='American Heritage International Inc.'>OTC:AHII</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442274\" data-linked=\"FDA draft guidance on e-cigs includes tighter restrictions on sales\" data-tweet=\"$MO $BTI $VAPE - FDA draft guidance on e-cigs includes tighter restrictions on sales https://seekingalpha.com/news/3442274-fda-draft-guidance-on-e-cigs-includes-tighter-restrictions-on-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3442274-fda-draft-guidance-on-e-cigs-includes-tighter-restrictions-on-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442273\" data-ts=\"1552483084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442273-clne-acb-and-cara-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CLNE, ACB and CARA among premarket gainers</a></h4><ul><li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/pr/17442685-positive-fda-meeting-outlines-path-ahead-akari-therapeutics-s-coversin-hematopoietic-stem\" target=\"_blank\">announcing</a> that it had a successful Type B, pre-IND meeting with the FDA.</li><li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"green\">+17%</font> on <a href=\"https://seekingalpha.com/news/3441999-pareteum-beats-0_01-beats-revenue\" target=\"_blank\">Q4 result</a>.</li><li>PAVmed (NASDAQ:<a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a>) <font color=\"green\">+15%</font> on <a href=\"https://seekingalpha.com/pr/17442613-pavmed-announces-portio-breakthrough\" target=\"_blank\">announcing</a> PortIO breakthrough.</li><li>Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings, Inc.'>AWSM</a>) <font color=\"green\">+13%</font>.</li><li>Cara Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics, Inc.'>CARA</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3441998-cara-therapeutics-beats-0_07-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) <font color=\"green\">+10%</font> on potential partnerships and <a href=\"https://seekingalpha.com/news/3442203-nelson-peltz-advise-aurora-cannabis-expansion-shares-8-percent-premarket\" target=\"_blank\">global expansion plans</a>.</li><li>Clean Energy Fuels (NASDAQ:<a href='https://seekingalpha.com/symbol/CLNE' title='Clean Energy Fuels Corp.'>CLNE</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3442006-clean-energy-fuels-beats-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3442239-vera-bradley-inc-beats-0_02-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Guardant Health (NASDAQ:<a href='https://seekingalpha.com/symbol/GH' title='Guardant Health, Inc.'>GH</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3442056-guardant-health-beats-0_05-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Everi Holdings (NYSE:<a href='https://seekingalpha.com/symbol/EVRI' title='Everi Holdings Inc.'>EVRI</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3442003-everi-holdings-beats-0_11-beats-revenue\" target=\"_blank\">Q4 earnings.</a></li><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/pr/17442654-trovagene-receives-approximately-3_0-million-exercise-warrants\" target=\"_blank\">receiving</a> $3M from exercise of warrants.</li><li>DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"green\">+6%</font>.</li><li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3442262-moleculin-bio-8-percent-premarket-potential-accelerated-review-annamycin\" target=\"_blank\">potential</a> accelerated review for Annamycin.</li><li>Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals Inc.'>CNAT</a>) <font color=\"green\">+6%</font> on the <a href=\"https://seekingalpha.com/pr/17442841-conatus-late-breaker-oral-presentation-easl-meeting-detail-results-encore-ph-phase-2b\" target=\"_blank\">acceptance</a> of an abstract for a late-breaker oral presentation at The International Liver Congress 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442273\" data-linked=\"CLNE, ACB and CARA among premarket gainers\" data-tweet=\"$AKTX $TEUM $PAVM - CLNE, ACB and CARA among premarket gainers https://seekingalpha.com/news/3442273-clne-acb-and-cara-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442273-clne-acb-and-cara-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442271\" data-ts=\"1552482992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442271-pdd-expr-and-zto-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDD, EXPR and ZTO among premarket losers</a></h4><ul><li>VivoPower International (NASDAQ:<a href='https://seekingalpha.com/symbol/VVPR' title='VivoPower International PLC'>VVPR</a>) <font color=\"red\">-21%</font>.</li><li>Navios Maritime Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a>) <font color=\"red\">-14%</font>.</li><li>Express (NYSE:<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a>) <font color=\"red\">-13%</font> on <a href=\"https://seekingalpha.com/news/3442177-express-beats-0_04-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3442021-verastem-beats-0_17-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3442002-synchronoss-technologies-eps-2_49\" target=\"_blank\">Q4 earnings</a>.</li><li>Pinduoduo (NASDAQ:<a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo Inc.'>PDD</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3442184-pinduoduo-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li>Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>) <font color=\"red\">-8%</font>.</li><li>Sigma Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/pr/17442086-sigma-labs-announces-proposed-public-offering-securities\" target=\"_blank\">announcing</a> stock offering.</li><li>Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics, Inc.'>SEEL</a>) <font color=\"red\">-6%</font>.</li><li>Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences Inc.'>SLDB</a>) <font color=\"red\">-6%</font> after <a href=\"https://seekingalpha.com/news/3442247-solid-biosciences-files-200m-mixed-shelf-offering\" target=\"_blank\">filing</a> $200M mixed shelf offering.</li><li>Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-6%</font>.</li><li>Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics, Inc.'>ALRN</a>) <font color=\"red\">-6%</font>.</li><li>Telaria (NYSE:<a href='https://seekingalpha.com/symbol/TLRA' title='Telaria, Inc.'>TLRA</a>) <font color=\"red\">-5%</font>.</li><li>ZTO Express (Cayman) (NYSE:<a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express &#40;Cayman&#41; Inc.'>ZTO</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/news/3442108-zto-express-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442271\" data-linked=\"PDD, EXPR and ZTO among premarket losers\" data-tweet=\"$VVPR $NM $EXPR - PDD, EXPR and ZTO among premarket losers https://seekingalpha.com/news/3442271-pdd-expr-and-zto-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3442271-pdd-expr-and-zto-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442267\" data-ts=\"1552482476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADDYY\" target=\"_blank\">ADDYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442267-adidasminus-3-after-outlook-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adidas -3% after outlook disappoints</a></h4><ul> <li>Adidas (<a href='https://seekingalpha.com/symbol/ADDYY' title='adidas AG'>OTCQX:ADDYY</a>) is <font color=\"red\">down 3.00%</font> in Frankfurt trading after the company's 2019 sales forecast for currency-neutral sales growth of 5% to 8% trails estimates slightly.</li> <li>Expected results from Adidas in North America and Europe lag expectations, while double-digit growth is anticipated out of Asia-Pacific.</li> <li>Adidas doesn't think Brexit will impact results this year or next.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442267\" data-linked=\"Adidas -3% after outlook disappoints\" data-tweet=\"$ADDYY - Adidas -3% after outlook disappoints https://seekingalpha.com/news/3442267-adidasminus-3-after-outlook-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3442267-adidasminus-3-after-outlook-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442263\" data-ts=\"1552482229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAK\" target=\"_blank\">NAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442263-northern-dynasty-raises-10m-for-pebble-project-via-bought-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northern Dynasty raises $10M for Pebble project via bought deal</a></h4><ul><li>Northern Dynasty Minerals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd.'>NAK</a>) <font color=\"red\">-7.7%</font> pre-market after saying it <a href=\"https://seekingalpha.com/pr/17442066-northern-dynasty-announces-us-10_0-million-bought-deal\" target=\"_blank\">raised $10M</a> to further advance its Pebble project in Alaska, as Cantor Fitzgerald leads a syndicate of underwriters in purchasing on a bought deal basis 15.625M shares at $0.64 each.</li><li>NAK also granted the underwriters an over-allotment option to  purchase up to an additional 2.34M-plus shares, which could raise  another $1.5M.</li><li>The U.S. Army Corps of Engineers <a href=\"https://seekingalpha.com/news/3435585-alaskas-pebble-mine-nearer-approval-environmental-impact-statement\" target=\"_blank\">last month</a> released a draft environmental impact statement for the  project, which shows no major data gaps or substantive  impacts associated with a mine at the Pebble site.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442263\" data-linked=\"Northern Dynasty raises $10M for Pebble project via bought deal\" data-tweet=\"$NAK - Northern Dynasty raises $10M for Pebble project via bought deal https://seekingalpha.com/news/3442263-northern-dynasty-raises-10m-for-pebble-project-via-bought-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3442263-northern-dynasty-raises-10m-for-pebble-project-via-bought-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442262\" data-ts=\"1552482073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442262-moleculin-bio-up-8-premarket-on-potential-accelerated-review-for-annamycin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin Bio up 8% premarket on potential accelerated review for Annamycin</a></h4><ul><li>Thinly traded nano cap Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) is up <font color=\"green\">8% </font>premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17442496-moleculin-files-fda-expedited-approval-pathway-annamycin\" target=\"_blank\">request</a> for Fast Track status from the FDA related to Annamycin for relapsed/refractory acute myeloid leukemia &#40;AML&#41;.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3442262\" data-linked=\"Moleculin Bio up 8% premarket on potential accelerated review for Annamycin\" data-tweet=\"$MBRX - Moleculin Bio up 8% premarket on potential accelerated review for Annamycin https://seekingalpha.com/news/3442262-moleculin-bio-up-8-premarket-on-potential-accelerated-review-for-annamycin?source=tweet\" data-url=\"https://seekingalpha.com/news/3442262-moleculin-bio-up-8-premarket-on-potential-accelerated-review-for-annamycin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442260\" data-ts=\"1552481825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442260-wedbush-heads-to-sidelines-on-american-outdoor-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush heads to the sidelines on American Outdoor Brands</a></h4><ul> <li>Wedbush drops American Outdoor Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a>) to a Neutral rating after having the firearms stock set at Outperform.</li> <li>The firm slides its price target to $11.</li> <li>AOBC is <font color=\"red\">down 0.94%</font> in premarket trading to $9.49. Shares are already down 25% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3442260\" data-linked=\"Wedbush heads to the sidelines on American Outdoor Brands\" data-tweet=\"$AOBC - Wedbush heads to the sidelines on American Outdoor Brands https://seekingalpha.com/news/3442260-wedbush-heads-to-sidelines-on-american-outdoor-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3442260-wedbush-heads-to-sidelines-on-american-outdoor-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3442259\" data-ts=\"1552481657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOAH\" target=\"_blank\">NOAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3442259-noah-holdingsminus-5_0-after-q4-transaction-value-drops\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Noah Holdings -5.0% after Q4 transaction value drops</a></h4><ul><li>Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">falls 5.0%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17442123-noah-holdings-limited-announces-unaudited-preliminary-financial-results-fourth-quarter-full\" target=\"_blank\">Q4 total transaction value</a> of RMB 25.2B fell 11% from RMB 28.2B a year earlier.</li><li>Q4 investment income of RMB 6.5M ($1M) fell from RMB 35.0M, primarily due to changes in fair value of the company's investments in equity securities.</li><li>Q4 non-GAAP net income attributable to Noah shareholders per diluted ADS was RMB 3.64 (53 cents) vs. RMB 2.92 in the year-ago period.</li><li>Q4 net margin was 18.4% vs. 21.7%; non-GAAP net margin attributable to Noah shareholders was 27.1% vs. 23.9%.</li><li>Sees 2019 non-GAAP net income attributable to Noah shareholders of RMB 1.13B-RMB 1.18B, an increase of 12%-17% from 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442106-noah-holdings-reports-q4-results\" target=\"_blank\">Noah Holdings reports Q4 results</a> (March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3442259\" data-linked=\"Noah Holdings -5.0% after Q4 transaction value drops\" data-tweet=\"$NOAH - Noah Holdings -5.0% after Q4 transaction value drops https://seekingalpha.com/news/3442259-noah-holdingsminus-5_0-after-q4-transaction-value-drops?source=tweet\" data-url=\"https://seekingalpha.com/news/3442259-noah-holdingsminus-5_0-after-q4-transaction-value-drops\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}